(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 June 2018 (28.06.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/114983 A1

(51) International Patent Classification:
C12R 1/46 (2006.01) *C12N 15/87* (2006.01)

(21) International Application Number:
PCT/EP2017/083601

(22) International Filing Date:
19 December 2017 (19.12.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
16205055.3 19 December 2016 (19.12.2016) EP

(71) Applicant: **DUPONT NUTRITION BIOSCIENCES APS** [DK/DK]; Langebrogade 1, 1411 Copenhagen K (DK).

(72) Inventors: **FREMAUX, Christophe**; 19 rue des Joncs, 86000 Poitiers (FR). **HORVATH, Philippe**; 9 rue de la Roseraie, 86100 Châtellerault (FR). **BOYAVAL, Patrick**; Les Ruisselées, 35520 La Meziere (FR). **HOLS, Pascal**; 39 Rue de Guelette, 5020 Vedrin (BE). **BLANDINE, David**; Place de Buzet 15, 5150 Floreffe (BE). **RADZIEJWOSKI, Amandine**; Rue François van Cutsem, 82, B-1140 Evere (BE). **FONTAINE, Laetitia**; Rue du Grand Hornu 21/004, B-1348 Louvain-la-Neuve (BE). **TOUSSAINT, Frédéric**; Rue Aviateur Huens, 37, 1330 Rixensart (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** METHODS AND STRAIN

(57) **Abstract:** The present invention relates to a method for transforming a strain of the Lactococcus genus through natural competence. The present invention further relates to strains obtained or obtainable by said method. The present invention also relates to a method for identifying a strain of the Lactococcus genus which is transformable through natural competence.

WO 2018/114983 A1

METHODS AND STRAIN

FIELD OF THE INVENTION

The present invention relates to a method for transforming a strain of the *Lactococcus* genus through natural competence. The present invention further relates to strains obtained or obtainable by said method. The present invention also relates to a method for identifying a strain of the *Lactococcus* genus which is transformable through natural competence.

BACKGROUND TO THE INVENTION

Lactococcus lactis is one of the most important lactic acid bacteria used in the dairy industry, in particular as a main dairy starter species in various cheese preparations (e.g. gouda, cheddar, brie, parmesan, roquefort) and fermented milk products (e.g. buttermilk, sour cream). Other applications of *L. lactis* bacteria include as a host for heterologous protein production or as a delivery platform for therapeutic molecules. While the growth and fermentation properties of *L. lactis* have been gradually improved by selection and classical methods, there is great potential for further improvement through natural processes or by genetic engineering. Of particular interest are methods to naturally transform *L. lactis* without the use of genetic engineering, thereby generating new non-GMO strains with useful industrial properties.

Lactococcus raffinolactis is present in a wide range of environments, such as foods (meat, fish, milk, vegetable), animals, and plant materials. In the dairy environment, this species has been found in raw milks (cow, ewe, goat, and camel), natural dairy starter cultures, and a great variety of cheeses. The prevalence of this bacterium in foods even if with a “nondominant” status compared to other lactococci could make it a candidate for future development of starter cultures.

DNA acquisition by natural transformation is widespread among prokaryotes and has been identified in over 80 species. Various functions are attributed to competence for natural transformation: genome plasticity, DNA repair, and/or nutrition. In Gram-positive bacteria, competence for natural transformation has been well-characterized in *Bacillus subtilis* and in various species of the genus *Streptococcus* (e.g. *S. pneumoniae, S. mutans*, and *S. thermophilus*).

In streptococci, competence for DNA transformation is induced in response to secreted signalling peptides referred to as competence pheromones/alarmones. The production of this class of cell-to-cell communication molecules is initiated in response to specific environmental stresses or conditions and allows the coordination of physiological functions (e.g. competence,

predation, biofilm formation). Above a threshold concentration, competence pheromones activate the master regulator ComX (alternative sigma factor σ^X), which ultimately leads to a transcriptional reprogramming of cells (globally known as late competence phase) including the induction of genes strictly required for DNA transformation. ComX binds to a specific DNA sequence named Com-box or Cin-box, which is located at least in the vicinity of promoters of late competence (*com*) genes/operons responsible for DNA uptake (*e.g.; comG*, *comF* and *comE* operons), DNA protection (e.g. *ssb*) and DNA recombination (*e.g. recA*, *dprA*, *coiA*), and positively controls their expression.

The early steps leading to competence activation (early competence phase) differs among bacteria. In streptococci, two major peptide-based signaling pathways - i.e. ComCDE and ComRS - have been identified so far. In mitis and anginosus groups of streptococci (*S. pneumoniae* as paradigm), the competence signaling peptide (CSP, or mature ComC) triggers a phosphorylation cascade mediated by the two-component system ComD-ComE, leading to the transcriptional activation of *comX*. In salivarius, mutans, pyogenes, bovis and suis groups of streptococci, another regulation mechanism is operational (*S. thermophilus* as paradigm). This system involves the ComX-induction peptide (XIP, or mature ComS) which is internalized by the oligopeptide transporter Opp, binds to and activates the regulator ComR, and in turn induces *comX* transcription.

Orthologues of *comX* and of all late *com* genes essential for natural transformation have been identified in the genome of *L. lactis*, although some are present as putative pseudogenes in different strains (*Wydau et al., 2006*).

Specific growth conditions have been reported to activate *com* genes in *Lactococcus lactis*. For example, the promoter of *comX* was shown to be induced during cheese-making conditions in strain MG5267 (an MG1363 derivative) which belongs to the subspecies *cremoris* (Bachmann et al. 2010).

In the *L. lactis* subspecies (subsp.) *lactis*, carbon starvation was shown to activate six late *com* genes in strain IL1403 of dairy origin (i.e. *comX, comEA*, *comGA*, *comGB*, *radA*, and *nucA)* and most of the late essential *com* genes in strain KF147 of plant origin (i.e. *comX*, *comC*, *coiA*, and operons *comG*, *comE*, *comF*) (*Ercan et al., 2015*). However, when the authors attempted to validate functional natural transformation in KF147, they were unsuccessful.

Wydau *et al*. reported that all the well-established late genes/operons display an upstream and conserved Com-box, suggesting that they are similarly controlled by ComX as reported in streptococci. However, the authors did not comment on whether *comX* over-expression in IL1403 induced natural competence. Indeed, the authors neither report any experiment

evaluating natural competence in this strain nor suggest any experimental conditions appropriate for inducing natural competence. Thus, as noted in the recent literature (*see Ercan et al., 2015*) [*i.e.,* 9 years after Wydau et al.], there is no experimental evidence for successful transformation of any species of the genus *Lactococcus* by natural competence, and even less of IL1403.

Accordingly, there remains a need for a method for naturally transforming *Lactococcus* strains using natural competence. In addition, since some strains of the *Lactococcus* genus may not encode a full set of functional late *com* genes, there is a need for a method for identifying *Lactococcus* strains which can be transformed by natural competence.

SUMMARY OF THE INVENTION

In a first aspect, the present invention provides a method for transforming a strain of the *Lactococcus* genus with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus* genus, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

In one embodiment, the step of modulating the production of a ComX protein is performed by expressing a *comX* gene in said strain or increasing the expression of a *comX* gene in said strain.

In a further embodiment, the *comX* gene is an exogenous *comX* gene. Said exogenous *comX* gene may be transferred into said strain by conjugation, transduction, or transformation. Said exogenous *comX* gene may be operably linked to transcription regulator(s).

In an alternative embodiment, said *comX* gene is the endogenous *comX* gene of said strain.

In one embodiment, when said *comX* gene is the endogenous *comX* gene of said strain, the method comprises:

(a) providing a strain of the *Lactococcus* genus, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein, by expressing the endogenous *comX* gene or increasing the expression of the endegenous *comX* of said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome,

wherein step (c) is carried out after step (b) or wherein step (b) and step (c) are carried out simultaneously.

In some embodiments, said ComX protein has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, or has at least 90% identity or at least 90% similarity to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22. In some embodiments, said ComX protein has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or has at least 90% identity or at least 90% similarity to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.

In some embodiments, said *comX* gene has the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, or has at least 90% identity to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19 or SEQ ID NO:21.

In some embodiments, said *comX* gene has the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or has at least 90% identity to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5.

In some embodiments, the medium of step (c) is a chemically defined medium. In a preferred embodiment the chemically defined medium (CDM) comprises 0.5 g/L NH_4Cl, 9.0 g/L KH_2PO_4, 7.5 g/L K_2HPO_4, 0.2 g/L $MgCl_2$, 5 mg/L $FeCl_2$, 50 mg/L $CaCl_2$, 5 mg/L $ZnSO_4$, 2.5 mg/L $CoCl_2$, 0.05 g/L tyrosine, 0.1 g/L asparagine, 0.1 g/L cysteine, 0.1 g/L glutamine, 0.1 g/L isoleucine, 0.1 g/L leucine, 0.1 g/L methionine, 0.1 g/L tryptophan, 0.1 g/L valine, 0.1 g/L histidine, 0.2 g/L arginine, 0.2 g/L glycine, 0.2 g/L lysine, 0.2 g/L phenylalanine, 0.2 g/L threonine, 0.3 g/L

alanine, 0.3 g/L proline, 0.3 g/L serine, 10 mg/L paraaminobenzoic acid, 10 mg/L biotin, 1 mg/L folic acid, 1 mg/L nicotinic acid, 1 mg/L panthotenic acid, 1 mg/L riboflavin, 1 mg/L thiamine, 2 mg/L pyridoxine, 1 mg/L cyanocobalamin, 5 mg/L orotic acid, 5 mg/L 2-deoxythymidine, 5 mg/L inosine, 2.5 mg/L *dl*-6,8-thioctic acid, 5 mg/L pyridoxamine, 10 mg/L adenine, 10 mg/L guanine, 10 mg/L uracil, 10 mg/L xanthine, and 5 g/L glucose.

In some embodiments, prior to step (c) said strain is incubated in a pre-culture medium, preferably wherein the pre-culture medium is a complex medium, more preferably wherein the pre-culture medium is M17G or THBG.

In some embodiments of the present invention, said strain is incubated with the exogenous DNA polynucleotide for around 4 to 8 hours at around 30 °C and said medium of step (c) is supplemented with an osmo-stablizer, preferably wherein the osmo-stablizer is glycerol or mannitol, more preferably wherein the osmo-stabilizer is 5% [v/v] glycerol or 5% [w/v] mannitol.

In some embodiments, said exogenous DNA polynucleotide is from a strain of the *Lactococcus lactis* species.

In some embodiments, said exogenous DNA polynucleotide is from a strain of the *Lactococcus raffinolactis* species.

In some embodiments, said strain of step (a) is a *Lactoccocus lactis* subsp. *cremoris* strain.

In another aspect, the present invention provides a strain of the *Lactococcus* genus obtained or obtainable by the method of the first aspect of the present invention.

In one embodiment, said strain of the *Lactococcus* genus is a strain of the *Lactococcus lactis* or *Lactococcus raffinolactis* species.

In a further aspect, the present invention provides a method for identifying a strain of the *Lactococcus* genus which is transformable through natural competence comprising the steps of:

(a) providing a strain of the *Lactococcus* genus species;

(b) transforming said strain with a plasmid expressing a *comX* gene having at least 90% identity, preferably having 100% identity, to the endogenous *comX* gene of said strain;

(c) contacting said strain obtained in step (b) with an exogenous DNA polynucleotide encoding a marker gene in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) determining the rate of recombination events;

wherein a rate of at least 1 x 10^{-6} transformants per µg of DNA is indicative of a strain which is transformable through natural competence.

In a particular embodiment of method for transforming a strain of the *Lactococcus* genus of the present invention, said strain of step (a) is identified using the method for identifying a strain of the *Lactococcus* genus which is transformable through natural competence according to the present invention. In some embodiments of the present invention, said strain of step (a) is identified using Assay A.

DESCRIPTION OF THE DRAWINGS

Figure 1: Table showing the status of genes involved in natural competence for *L. lactis* strains MG1363, SK11, KW2, IL1403, SL12651 and SL12653.

Late *com* genes in the complete genomes of strains MG1363, SK11, and KW2 of *Lactococcus lactis* subsp. *cremoris* and of strain IL1403, SL12651 and SL12653 of *Lactococcus lactis* subsp. *lactis*. Origin is indicated above strain names. Gene-associated function in DNA transformation is indicated on the left. Reg. denotes regulation. The complete and incomplete status of late genes is based on blastp and tblastn homology searches (https://blast.ncbi.nlm.nih.gov/Blast.cgi) using orthologues of *S. pneumoniae* TIGR4 and *S. thermophilus* LMD-9 and default parameters. + denotes the presence of a complete gene; * denotes the presence of an incomplete gene due to nucleotide(s) exchange, insertion or deletion resulting in a premature stop codon; and Tn denotes a disrupted gene by the insertion of at least one transposon.

Figure 2: Graphs displaying the results of luciferase assays which demonstrate the activation of a reporter construct comprising the late promoter P_{comGA} driven by constitutive *comX* overexpression

(**A**) Maximum specific luciferase (Lux) activity (RLU OD_{600}^{-1}) emitted by eight independent clones (cl01 to cl08) of the KW2-derived reporter strain (BLD101, $P_{comGA[MG]}$-*lux*AB) carrying plasmid pGhP32comX_{MG} compared to the control strain (Ctl) carrying the empty vector pG$^+$host9. (**B**) Kinetics of specific Lux activity (solid line) during growth (RLU/OD600; dotted line) for the control strain (Ctl; black lines) and three selected clones (BLD101 [pGhP32comX_{MG}], cl02, cl04 and cl05; gray lines). (**C**) Kinetics of specific luciferase activity (closed symbols) during growth (RLU/OD600; open symbols) of the MG1363 + pGhP32comX_{MG}-$P_{comGA[MG]}$-*luc*, grown in M17G at 30°C. (**D**) Kinetics of specific luciferase activity (closed symbols) during growth (RLU/OD600; open symbols) of IL1403 + pGhP32comX_{IO}-$P_{comGA[IO]}$-*luc* strains, grown in M17G at 30°C.

Figure 3: Graphs displaying the results of luciferase assays which demonstrate the impact of growth medium on P_{comGA} activation

Maximum specific Lux activity of BLD101 [pGhP32comX_{MG}] cl02 grown in different final culture media (CDM, THBG, and M17G) according to preculture conditions (CDM, THBG, and M17G). Overnight precultures were 10-fold diluted in the pre-culture medium and grown for 2 hours. Then, cells were washed twice in distilled water and the OD_{600} was adjusted to 0.05 in the final growth medium before measuring growth and luciferase activity. One representative experiment of two independent replicates.

Figure 4: Results of a transformation assay implemented on a *L. lactis* subsp. *cremoris* KW2 constitutively expressing *comX* contacted with a DNA consisting of a mutated allele of the *rpsL* gene as exogenous DNA polynucleotide

(**A**) Alignment of the *rpsL* gene sequences of strain MG1363, a spontaneous streptomycin-resistant clone of strain MG1363, strain KW2 and a KW2-derived transformant obtained using the method of the invention (partial sequence). The arobase, pound and dollar signs below the alignment indicate the positions of nucleotide differences existing between the *rpsL* sequences. The dollar sign at position 167 indicates the point mutation (A→T; *strA1* allele) responsible for the streptomycin-resistance phenotype; the pound sign at position 156 highlights a nucleotide that is naturally different between MG1363 and KW2 (T in KW2, A in MG1363); the arobase sign at position 39 indicates a silent nucleotide substitution (T→G) which is found in the streptomycin-resistant clone derived from MG1363. (**B**) DNA transformation with the s*trA1* allele was assessed for *L. lactis* strains constitutively expressing ComX. Transformation rate (white bars) and maximum specific luciferase (Lux) activity (black diamonds, RLU OD_{600}^{-1}, as reported in Figure 2) of eight clones (cl01 to cl08) of the reporter strain (BLD101, $P_{comGA[MG]}$-*luxAB*) carrying plasmid pGhP32comX_{MG} compared to the negative control strain (Ctl-) carrying the empty vector (BLD101 [pG^{+}host9]).

Figure 5: Graphs displaying the results of transformation rate of the KW2 derivative BLD101 [pGhP32comX_{MG}] obtained with overlap PCR products (*comEC*, *mecA*, *ciaRH*, *covRS* and *clpC*) and *strA1* (*rpsL)- donor DNA.**

The threshold represents the theoretical transformation rate to obtain only one transformant.

Figure 6: Graphs depicting the results of transformation assays for a *L. lactis* subsp. *cremoris* deleted in its *comEC* gene and constitutively expressing *comX*.

DNA transformation with the s*trA1* allele was assessed for *L. lactis* strains constitutively expressing *comX.* Transformation rate (white bars) and maximum specific luciferase (Lux) activity (RLU OD_{600}^{-1}) of four clones (cl01 to cl04) of the ComEC-deficient reporter strain

(BLD102, $P_{comGA[MG]}$-*luxAB*) carrying plasmid pGhP32comX_{MG} compared to the positive (Ctl^+, BLD101 [pGhP32comX_{MG}] cl02) and negative (Ctl^-, BLD101 [pG^+host9]) control strains. Transformability was assessed according to the standard protocol described in Materials and Methods using *strA1*-carrying PCR products as donor DNA. ND denotes a transformation rate below the detection level of spontaneous Str^r mutants (< 10^{-7}). One representative experiment of two independent replicates.

Figure 7: Graphs displaying natural competence in *Lactococcus lactis subsp. lactis* SL12651 and 12653 strains.

(A) Transformation rate of *L. lactis subsp. lactis* SL12651 and 12653 strains in M17G medium, with *rpsL** donor DNA (+DNA) or without donor DNA (-DNA); (B) DNA transformation with increasing initial concentration of donor DNA assessed in SL12653 strain; (C) Comparison of transformation rates between wild-type (WT) SL12653 strain and a SL12653 strain deleted for the *comX* gene (ComX-); transformation rate of three clones of the ComX-deficient strain compared to the WT strain, in presence (+DNA) or in absence (-DNA) of donor DNA.

DETAILED DESCRIPTION

The present invention is based on the observation that overexpression of ComX in a strain of the *Lactococcus* genus allowed to transform this strain by natural competence. Using this approach a *L. lactis* strain was generated by natural transformation with an exogenous DNA polynucleotide. Importantly, these results are the first demonstration of transformation of a *L. lactis* strain by natural competence. Further, existence of natural competence in the *Lactococcus* genus has been confirmed in two strains of the *Lactococcus raffinolactis* species and two *Lactococcus lactis* species.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, biochemistry, microbiology, bacteriology, and related fields, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature.

Thus, the present invention provides a method for transforming a strain of the *Lactococcus* genus with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus* genus, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

As detailed below, step (b) and step c) can be carried out sequentially [i.e., step (b) and then step (c)] or in another embodiment step (b) and step (c) can be carried out simultaneously.

***Lactococcus* genus**

The present invention relates to a method for transforming a strain of the *Lactococcus* genus, a Gram-positive bacterium. *Lactococcus* strains are known as lactic acid bacteria (LAB) for their ability to convert carbohydrate to lactic acid. A strain of the *Lactococcus* genus and *Lactococcus* strain are used herein interchangeably.

The *Lactococcus* genus comprises, but is not limited to the following species: *Lactococcus chungangensis, Lactococcus fujiensis, Lactococcus garvieae, Lactococcus lactis, Lactococcus piscium, Lactococcus plantarum* and *Lactococcus raffinolactis*. Any strain of one of these species may be used in the current invention, provided that this strain is transformable through natural competence as defined herein.

In a particular embodiment, said strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus lactis* species or a strain of the *Lactococcus raffinolactis* species.

Lactococcus lactis

In a particular embodiment, said strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus lactis* species. The *species Lactococcus lactis* comprises several subspecies. Thus, when the strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus lactis* species, said strain is selected in the group consisting of *Lactococcus lactis* subsp. *cremoris*, *Lactococcus lactis* subsp. *hordniae, Lactococcus lactis* subsp. *lactis* and *Lactococcus lactis* subsp. *tructae*. As used herein a strain of the *Lactococcus lactis* species is understood to be a genetic variant or subtype of any *L. lactis* species or subspecies. The different *Lactococcus lactis* subspecies disclosed here, and in particular the *lactis* and the *cremoris* subspecies, are defined herein based on DNA sequences coding for 16S ribosomal RNA [*Ward et al., 1998*].

In a particular aspect, the present invention provides a method for transforming a strain of the *Lactococcus lactis* species with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus lactis* species, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

In a preferred embodiment, the strain of step (a) is a *Lactococcus lactis* subsp. *cremoris* strain or a *Lactococcus lactis* subsp. *lactis* strain. Both subspecies have been identified and characterised with full genome sequences – see, e.g., *Wegmann et al*. (2007) J. Bacteriol. 189:3256-3270 and *Bolotin et al.* (2001) Genome Res. 11:731–753. With regards to the dairy industry, *L. lactis* subsp. *lactis* (previously known as *Streptococcus lactis*) is preferred for making soft cheese while *L. lactis* subsp. *cremoris* (previously known as *Streptococcus cremoris)* is preferred for hard cheese production.

In a preferred embodiment, the strain of step (a) is *Lactococcus lactis* subsp. *cremoris* strain.

In another preferred embodiment, the strain of step (a) is *Lactococcus lactis* subsp. *lactis* strain.

Lactococcus raffinolactis

In a particular embodiment, said strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus raffinolactis* species.

In a particular aspect, the present invention provides a method for transforming a strain of the *Lactococcus raffinolactis* species with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus raffinolactis* species, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

Lactococcus plantarum

In a particular embodiment, said strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus plantarum* species.

In a particular aspect, the present invention provides a method for transforming a strain of the *Lactococcus plantarum* species with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus plantarum* species, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

Lactococcus piscium

In a particular embodiment, said strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus piscium* species.

In a particular aspect, the present invention provides a method for transforming a strain of the *Lactococcus piscium* species with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus piscium* species, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

Lactococcus garvieae

In a particular embodiment, said strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus garvieae* species.

In a particular aspect, the present invention provides a method for transforming a strain of the *Lactococcus garvieae* species with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus garvieae* species, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

Lactococcus fujiensis

In a particular embodiment, said strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus fujiensis* species.

In a particular aspect, the present invention provides a method for transforming a strain of the *Lactococcus fujiensis* species with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus fujiensis* species, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

Lactococcus chungangensis

In a particular embodiment, said strain of the *Lactococcus* genus of step a) is a strain of the *Lactococcus chungangensis* species.

In a particular aspect, the present invention provides a method for transforming a strain of the *Lactococcus chunganensis* species with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus chungangensis* species, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

DNA acquisition

Bacteria may naturally acquire exogenous DNA *via* one of three possible mechanisms: transformation, conjugation, or transduction.

As used herein the term "transformation" refers to the uptake of exogenous genetic material (e.g. a DNA polynucleotide) from the external medium. Since transformation requires that genetic material cross the bacterial cell wall and membrane and the uptake of exogenous genetic material is energetically costly, the process is tightly regulated. Accordingly, bacterial cells may only be transformed under certain conditions. Bacterial cells which are in a transformable state are said to be competent.

Competence may be artificially induced in the laboratory, e.g. by electroporation or exposure to divalent cations (e.g. $CaCl_2$) and heat shock. Alternatively, some species of bacteria express a proteinaceous machinery that provides natural competence; this system of natural competence has been widely studied in streptococci.

As used herein the term "conjugation" refers to the transfer of genetic material between bacterial cells.

As used herein the term "transduction" refers to the transfer of genetic material from a virus (e.g. a bacteriophage) or a viral vector into bacterial cell.

ComX protein

The method of the present invention comprises the step of modulating the production of a ComX protein in said strain.

ComX protein is an alternative sigma factor, also known as σ^X, which acts as master regulator for the late *com* genes and is responsible for transcriptional reprogramming of cells including the induction of genes strictly required for DNA transformation (*Lee et al.*, 1989; *Petersen et al.* 2004).

ComX may bind to a specific target sequence (or box) termed the Com-box (or Cin-box). Com-boxes are located in the vicinity of the promoters of late competence (*com*) genes/operons responsible for DNA uptake (e.g., *comG*, *comF,* and *comE* operons), DNA protection (e.g. *ssb*) and DNA recombination (e.g. *recA*, *dprA*, *coiA*), and positively controls their expression (*Campbell et al.,* 1998; *Luo and Morrison*, 2003).

The production of the ComX protein in a strain of interest may be increased relatively to an appropriate control strain, i.e., the *Lactococcus* strain in which the production of the ComX protein has not been modulated. ComX protein may be produced (expressed) following modulation as compared to an appropriate control strain, i.e., the *Lactococcus* strain in which the ComX protein is not produced.

In some embodiments, the production of the ComX protein is constitutive or inducible.

The production of ComX protein may be monitored using any method known in the art. For example, by western blotting using an antibody specific for the ComX protein. Alternatively, *comX* gene mRNA transcript levels may be measured by qPCR.

Alternatively, the ComX protein may be monitored using a reporter construct polynucleotide, e.g. as described in the Example 1 and Materials and Methods. The reporter construct polynucleotide may comprise genes encoding one or more reporter proteins, preferably the genes encoding the reporter proteins are operably linked to a promoter comprising a Com-box sequence. The reporter proteins may be LuxAB or Luc. Accordingly, ComX expression (and activity) may be detected and measured using a luciferase assay (*Fontaine et al*., 2010).

In some embodiments of the method of the present invention, the step of modulating the production of a ComX protein is performed by expressing a *comX* gene in said strain or increasing the expression of a *comX* gene in said strain. In a particular embodiment, the step of modulating the production of a ComX protein is performed by expressing a *comX* gene in said strain in some growth conditions, whereas said strain does not express the ComX protein outside of these growth conditions. In a particular embodiment, the step of modulating the production of a ComX protein is performed by increasing the expression of a *comX* gene in said strain in some growth conditions.

The *comX* gene may be an exogenous *comX* gene. As used herein an “exogenous *comX* gene” is understood to be a *comX* gene which is brought into the cytoplasm of the *Lactococcus* strain of step a), in order to be expressed. The exogenous *comX* gene may have the same sequence as the *comX* gene found in the genome of the *Lactococcus* strain of step a) or may have a different sequence from the *comX* gene found in the genome of the *Lactococcus* strain

of step a). When different, the *comX* gene may be derived from a strain of a different species, a different subspecies or a different strain of *Lactococcus*.

The exogenous *comX* gene may be integrated within the genome of said *Lactococcus* strain.

Alternatively, the exogenous *comX* gene may be located within a vector. The vector may be selected from a plasmid, a viral vector (e.g. a phage), a cosmid, or a bacterial artificial chromosome.

Said plasmid may be transferred into said *Lactococcus* strain by conjugation, transformation or transduction. Said plasmid may be auto-replicative in the transformed *Lactococcus* strain or not.

The exogenous *comX* gene may be operably linked to transcription regulator(s). The exogenous *comX* gene may be located in a linear or circular polynucleotide.

Alternatively, in some embodiments of the method of the present invention, the *comX* gene is the endogenous *comX* gene of said *Lactococcus* strain. As used herein "the endogenous *comX* gene of said strain" is understood to be a *comX* gene that is naturally present in the genome of said strain.

In some embodiments, said *comX* gene is a *Lactococcus comX* gene. In an embodiment, said *comX* gene is a *Lactococcus lactis comX* gene. In a particular embodiment, said *comX* gene is a *Lactococcus lactis subsp. lactis comX* gene. In a particular embodiment, said *comX* gene is a *Lactococcus lactis subsp. cremoris comX* gene.

The *comX* gene may comprise or consist of a nucleotide sequence selected from the group consisting of:

- SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19; SEQ ID NO:21;

- a nucleotide sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19; SEQ ID NO:21;

- a variant of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 encoding respectively a ComX protein of SEQ ID NO:2, SEQ ID NO:4, SEQ ID

NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22; and

- a variant of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 encoding respectively a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22.

ATAACATATTACTTGGAAGAAGAGGATTTTGAAAATCTTTTTTCAGAAATGAAACCTATAGTTATGAA
ATTAATGAAACAAATTCGCATTAGAACATGGAAAATAGAGGATTATCTTCAAGAGGGGATGATTATTT
TACATCTTCTATTAGAAGAGCAGAACGATGGTCAAAAGCTGCATACAAAATTTAAGGTAAAGTATCAT
CAAAGATTAATAGATGAATTAAGACGAAGTTATGCAAAGAAACGAAGCCATGACCATTTTATAGGTTT
AGATGTTTATGAATGCTCAGACTGGATAAATTCAGGTGATACTAGTCCAGATAATGAAGTGGTCTTCA
ATCATTTGCTGGCAGAAGTATATGAAGGTTTGAGCGCACATTATCAAGACTTACTACTTCGACAAATG
CGAGGAGAAGAACTAACTCGCATGCAACGGTATCGCCTTCGTGAAAAAATAAAGGCCATCTTATTTTC
AGAAGACGAAGAGTGA **[SEQ ID NO:1]**

MTYYLEEEDFENLFSEMKPIVMKLMKQIRIRTWKIEDYLQEGMIILHLLLEEQNDGQKLHTKFKVKYH
QRLIDELRRSYAKKRSHDHFIGLDVYECSDWINSGDTSPDNEVVFNHLLAEVYEGLSAHYQDLLLRQM
RGEELTRMQRYRLREKIKAILFSEDEE **[SEQ ID NO:2]**

ATGACATATTACCTGGAAGAAAATGAATTCGAAGGTTTATTTTCTGGAATGAAACCAATCATCAGAAA
ATTGATGAAACAAATTCGAATCAAAGCATGGGACATAGAGGATTATTATCAAGAAGGAATGATTATTT
TGCATCACCTTTTAGAAGAAAATCACCCATCCACTAATATTTATACAAAGTTCAAAGTAAAATATCAT
CAACATTTGATTGATGAACTACGCCATAGCTACGCCAAAAAACGGCTTCATGACCATTTTGTAGGTCT
GGACATTTATGAATGTTCGGACTGGATAGATGCAGGAGGAAGTACCCCTGAAAGCGAGCTTGTGTTCA
ATCATCTTTTAGCAGAAGTTTATGAAGGATTGAGCGCCCACTATCAGGAATTACTCGTGCGTCAAATG
AGAGGAGAAGAACTCACGCGAATGGAACGCTATCGGCTAAGAGAAAAAATCAAAAATATACTATTTTC
TCGAGATGATGATTAA **[SEQ ID NO:3]**

MTYYLEENEFEGLFSGMKPIIRKLMKQIRIKAWDIEDYYQEGMIILHHLLEENHPSTNIYTKFKVKYH
QHLIDELRHSYAKKRLHDHFVGLDIYECSDWIDAGGSTPESELVFNHLLAEVYEGLSAHYQELLVRQM
RGEELTRMERYRLREKIKNILFSRDDD **[SEQ ID NO:4]**

ATGGATGACATTCAAGAAAAATACGGTTTAGAATTCAACGAATTATTCTCTGAGATGCGGCCGATAAT
TTATAAATTGATGAAGCAATTGCACATCAACACATGGGATTACGATGATTACTTCCAAGAGGGAATGA
TTACACTACATGAATTGCTGCAGAAAATTACAAATTTAGATCATGTACATACGAAATTTAAAGTGGCT
TACCATCAGCACTTAATTGACGAAATTCGCCATATTAAAGCACGAAAAAGAGGTTTTGATCAGCTCCA
TCCGATCAATGTTTATGACTGCGCAGATTGGATTGGCTCAAACCTTGCTACACCTGAAAGCGAGATAG
TTTTCAACCATCTACTAGAAGAAGTTTATGATAAACTTTCAACACACTATAAAGAACTGTTGGTAAAG
CAAATGCATGGGGAACATCTTACGAGAATGCAGAAGTATCGTTTAAAGGAAAAAATTAAAGCGATTTT
ATTTGATGAAGACTAA **[SEQ ID NO:5]**

MDDIQEKYGLEFNELFSEMRPIIYKLMKQLHINTWDYDDYFQEGMITLHELLQKITNLDHVHTKFKVA
YHQHLIDEIRHIKARKRGFDQLHPINVYDCADWIGSNLATPESEIVFNHLLEEVYDKLSTHYKELLVK
QMHGEHLTRMQKYRLKEKIKAILFDED **[SEQ ID NO:6]**

ATGGATAAAATTGAAACCATACTTAAAAGTATTGAACCGATTATTATGAACTGTCGGAAAAAAACTAA
AATTCCTTCCTGGGAATTAGACGACTATATGCAGGAAGGGATGATTATTGCTTTAGAGATGTACCATC
AACTCTTATTAGATCCACCAGATGATGACTTTAACTTCTATGTCTATTTCAAAGTCAGGTATTCTTGT

TTCTTAATTGATCACTATCGCAAAGCTATGGCAGTCAAGAGAAAATTCGACCAGCTTGACTATTGTGA
ACTTTCTGAGTCTGTTAATCTTTTTGATCACAAACAAAATGTGTCTGAAAACGTCATGTATAACTTGT
TGTGTCAAGAAATACACTTGGTTTTATCCCCGGAGGAGCTCAAGCTTTTTGAGGCACTTATTTGA
[SEQ ID NO:7]

MDKIETILKSIEPIIMNCRKKTKIPSWELDDYMQEGMIIALEMYHQLLLDPPDDDFNFYVYFKVRYSC
FLIDHYRKAMAVKRKFDQLDYCELSESVNLFDHKQNVSENVMYNLLCQEIHLVLSPEELKLFEALI
[SEQ ID NO:8]

ATGGATAGCATAGAAATGATGCTTCAAAATATTGAGCCAATTATTATGAATTGTAGTAAAACAACTAG
GATTCCATCTTGGGAGCTAGATGATTACATGCAGGAGGGGATGATTATTGCACTGGAAATGTATCAAA
ATAGACATAACATCAATAACGGTAACGCGTTTAATTTCTATGTCTATTTTAAAGTCAGGTATTCCTGT
TACCTGATAGATAGTTTTAGAAAGGCTAACGCATATAAAAGAAAATTTGATCAACCATTATATTGTGA
AATATCTGAAGCCTTCAACCTTTATGATCACCACCAAAATGTTGCAGACAATGTCTGTTATCAGCTAT
TGCAAGTTGAAATTCTTGAGATATTAACACCAGATGAAGCTGATTTATTTATGACCTTGAAAAATGGT
GGGAAAGTAGAGAGAAATAAAAAGTATAGATTAAAGAAAAAAATTATTGATTATCTTAAAGACATGTT
ATGA **[SEQ ID NO:9]**

MDSIEMMLQNIEPIIMNCSKTTRIPSWELDDYMQEGMIIALEMYQNRHNINNGNAFNFYVYFKVRYSC
YLIDSFRKANAYKRKFDQPLYCEISEAFNLYDHHQNVADNVCYQLLQVEILEILTPDEADLFMTLKNG
GKVERNKKYRLKKKIIDYLKDML **[SEQ ID NO:10]**

ATGGAGACTTTAGAAGCCATGCTCAAAAACATTGAACCTATTATTATGAATTGTCAAAAGATGGCAAA
AATACCTTCCTGGGATATTGACGATTATATGCAGGAGGGGAGGATCATTGCATTAGACTTGTATAATC
AGCTAGCAGAAAGAATGGAGACGGATGAGGTGAACTTTTACGTCTACTTCAAAGTCAGATATACCTGT
TTCTTGATTGATACTTACCGTAAGACAAATGCCTTTAAAAGAAAATTTGACCAACCGATTTACTTAGA
TGTATCCGAAGCATTTAATCTGTATGATCATAAGCAGAATGTCGCTGATAATGTCATGTATACTTTAT
TGCATCAGGAGATTCTAGACATCTTAACGCCTGTAGAAATTCAAACGCTAAACGCACTAAAAAGGGGA
GAAAAGGTCGACCGCAATAAAAAATTTAGGATTAAAAAGAAGATTATCAACTATATTAATCAGATTTT
CTAG **[SEQ ID NO:11]**

METLEAMLKNIEPIIMNCQKMAKIPSWDIDDYMQEGRIIALDLYNQLAERMETDEVNFYVYFKVRYTC
FLIDTYRKTNAFKRKFDQPIYLDVSEAFNLYDHKQNVADNVMYTLLHQEILDILTPVEIQTLNALKRG
EKVDRNKKFRIKKKIINYINQIF **[SEQ ID NO:12]**

ATGGAGCATAATTTAGATATGGAGCAGCTGGAAGAAATTTTTCATTCTGTCCAACATATTGTGTGGAA
GAACAGTCGTTTGATTCCGATAAATTTTTGGACGTTTGATGACTATCAGCAGGAAGGGCGCTTGGTAT
TATACGATTTGCTGGGAGATGGTGTGACGCAAAGGAACTTATTTTGCCATTTTAAGGTACGCTATAAG
CAGAGACTTATTGATATTAAAAGAAGGGAGCGGGCTTTTAAAAGGGGTTTTGATTGCGGGACTGGCTT
AGATATATACGAATATTCTGATGCTCTAAAGGGGAAAGCAGCCAGTCCAGAACATATCCTGATTTCTG
GAAGTTTACTTGAAGAAGTTTTTGAAAACTTAAATTTACGCTACCGACGGCTCCTCAAAAGTTACCTC
GCCGGCGATGAATTGCACCGTATGGAAAAGTATCGTTTGAAGGAAAAAATAACGAATATATTATATGA
ACAGCAGTGA **[SEQ ID NO:13]**

MEHNLDMEQLEEIFHSVQHIVWKNSRLIPINFWTFDDYQQEGRLVLYDLLGDGVTQRNLFCHFKVRYK
QRLIDIKRRERAFKRGFDCGTGLDIYEYSDALKGKAASPEHILISGSLLEEVFENLNLRYRRLLKSYL
AGDELHRMEKYRLKEKITNILYEQQ **[SEQ ID NO:14]**

ATGGCAGAAAATAATTTAGATAAAGAACAGCTTGAAGAGTTATTCCATTCACTTCAACATATTGTTTG
GAAGAACAGTCATTTAATTAAAATAAATTTTTGGACAATGGATGATTATCAGCAAGAAGGGCGACTGG
TTTTATACCAGTTACTTGAAGATGGCGTGACACAGGAAAAACTATTTTGCCATTTTAAAGTGCGATAT
AAGCAACGGTTGATTGATATAAAAAGACGAGAAAGAGCATTTAAGCGGGGTTTTGATTGTGGGGCTGG
TTTAGATATATATGAGTATTCTGATGCCCTGAAAGGCAAAGCTACCAGTCCTGAATATAACTTAATTT
CAGTTACTTTACTTGAAGAGGTTCATCAAAGTTTGAGTTTGAGATACCGCAATTTATTGGAGAATCAT

CTGTCAGGAGTGGAGTTGCATCGAATGGAAAAATACCGTTTAAAGGAAAAAATCAAGAGAATACTCTA
TGAAGAAGAATGA **[SEQ ID NO:15]**

MAENNLDKEQLEELFHSLQHIVWKNSHLIKINFWTMDDYQQEGRLVLYQLLEDGVTQEKLFCHFKVRY
KQRLIDIKRRERAFKRGFDCGAGLDIYEYSDALKGKATSPEYNLISVTLLEEVHQSLSLRYRNLLENH
LSGVELHRMEKYRLKEKIKRILYEEE **[SEQ ID NO:16]**

ATGGAGCATAATTTAGATATGGAGCAGCTGGAAGAGATATTTCATTCTGTTCAACATATTGTATGGAA
GAATAGTCGTTTGATTCCGATAAATTTTTGGACGATAGATGACTATCAGCAGGAAGGGCGTTTGGTAT
TATATGATTTACTTGAGGATGGTGTGACACAAAGAAAACTTTTTTGCCATTTTAAAGTACGTTATAAG
CAGAGACTTATTGATATTAAAAGAAGGGAGCGGGCTTTTAAAAGGGGTTTTGACTGTGGGACTGGGCT
AGATATTTACGAATATTCAGATGCTTTAAAAGGAAAAGTAGCCAGTCCAGAACATACTCTGATTTCTG
GCAGTTTGCTTGAAGAAGTTTTAGAAAACTTAAATTTACGCTACCGTGCTCTTCTTAAAAGTTACCTT
GCTGGTGATGAACTGCATCGAATGGAAAAACATCGTTTGAAAGAAAAAATAATAAAAATATTATATGA
TGAACAGTGA **[SEQ ID NO:17]**

MEHNLDMEQLEEIFHSVQHIVWKNSRLIPINFWTIDDYQQEGRLVLYDLLEDGVTQRKLFCHFKVRYK
QRLIDIKRRERAFKRGFDCGTGLDIYEYSDALKGKVASPEHTLISGSLLEEVLENLNLRYRALLKSYL
AGDELHRMEKHRLKEKIIKILYDEQ **[SEQ ID NO:18]**

TTGAAACCGATCGTTTCAAAATCTATGAGAACATTAAAAATCAATTTTTGGACTACAGAGGATTATCA
TCAAGAGGGTCTAATTACATTAAATGAAATATTAAATTCAGGATGTAAGGAGTCACAACTATACATTC
ACTTTAAAGTCAAATATCGACAAAAGCTAATAGACGTGATTAGAAAATCACAGGCGCAAAAAAGAATC
TGGGATAATGCAGAGAGTATTGATGTTTACGAATCTGAAAATCAAATTAATTCCAGTAACTCAAACCC
CGAAGACATAATAGTCTATGACAGTCTTGTAAAGGAAGTAATAACAAAATTAACACCTTCATACCGGA
AACTACTGAAACGACATCTAAGAGGTGAGGATGTGACAAGGATGGAAAAATACAGACTGAAGGAACGA
ATCAAACAAATTTTATTTGATGGTGATTGA **[SEQ ID NO:19]**

MKPIVSKSMRTLKINFWTTEDYHQEGLITLNEILNSGCKESQLYIHFKVKYRQKLIDVIRKSQAQKRI
WDNAESIDVYESENQINSSNSNPEDIIVYDSLVKEVITKLTPSYRKLLKRHLRGEDVTRMEKYRLKER
IKQILFDGD **[SEQ ID NO:20]**

ATGGATAAGATTGAAACCATACTTAAAAATATTGAACCGATTATCATGAACTGTCGAAAAAAAACTAA
CATCCCTTCCTGGCAATTAGACGACTATCTCCAGGAAGGCATGATTATTGCTCTAGAGATGTATCATC
AACTTTTATTAGACCCACCAGATGATGACTTTAACTTCTATGTTTATTTCAAAGTGAGATATTCTTGT
TTCTTGATTGATCAGTATCGGAGAAACATGGCTGTCAAAAGAAAATTCGACCAGATTGACTATTGTGA
ACTATCTGAGGCGTTTTATCTTTTTGATCAAAATCAAGATGTCTCTGAAAACGTCATGTATAATTTGT
TATGTCAAGAAATACACTTGCTTCTATCTCCTGAAGAACGAGAGCTTTTTGAGGCACTTAAAAATGGA
CAGAAGATTGACCGTAATCAAAAGTTTCGTATCAAGAAGAAAATTATTGAATATATTAAGAGGTTTTG
GTGA **[SEQ ID NO:21]**

MDKIETILKNIEPIIMNCRKKTNIPSWQLDDYLQEGMIIALEMYHQLLLDPPDDDFNFYVYFKVRYSC
FLIDQYRRNMAVKRKFDQIDYCELSEAFYLFDQNQDVSENVMYNLLCQEIHLLLSPEERELFEALKNG
QKIDRNQKFRIKKKIIEYIKRFW **[SEQ ID NO:22]**

In some embodiments, said *comX* gene has the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5 or has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5 or is a variant of SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5 encoding respectively the ComX protein of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 or is a variant of SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5 encoding respectively a functional ComX protein having at least 90% identity or at

least 90% similarity to a ComX protein of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6. In a particular embodiment, said *comX* gene is used when the *Lactococcus* strain in step a) is a *Lactococcus lactis* strain.

In a particular embodiment, when the strain of step a) is a *Lactococcus lactis* subsp. *lactis* strain, the *comX* gene comprises the nucleotide sequence of SEQ ID NO:1, any sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO:1, a variant of SEQ ID NO:1 encoding the ComX protein of SEQ ID NO:2 or a variant of SEQ ID NO:1 encoding a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:2.

In a particular embodiment, when the strain of step a) is a *Lactococcus lactis* subsp. *cremoris* strain, the *comX* gene comprises the nucleotide sequence of SEQ ID NO:3 or SEQ ID NO:5, any sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO:3 or SEQ ID NO:5 or a variant of SEQ ID NO:3 or SEQ ID NO:5 encoding respectively the ComX protein of SEQ ID NO:4 or SEQ ID NO:6 or a variant of SEQ ID NO:3 or SEQ ID NO:5 encoding respectively a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:4 or SEQ ID NO:6.

In some embodiments, said *comX* gene has the nucleotide sequence of SEQ ID NO:7 or has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO:7 or is a variant of SEQ ID NO:7 encoding the ComX protein of SEQ ID NO:8, or is a variant of SEQ ID NO:7 encoding a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:8. In a particular embodiment, said *comX* gene is used when the *Lactococcus* strain in step a) is a *Lactococcus raffinolactis* strain.

In some embodiments, said *comX* gene has the nucleotide sequence of SEQ ID NO:9 or has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO:9 or is a variant of SEQ ID NO:9 encoding the ComX protein of SEQ ID NO:10, or is a variant of SEQ ID NO:9 encoding a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:10. In a particular embodiment, said *comX* gene is used when the *Lactococcus* strain in step a) is a *Lactococcus plantarum* strain.

In some embodiments, said *comX* gene has the nucleotide sequence of SEQ ID NO:11 or has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least

96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO:11 or is a variant of SEQ ID NO:11 encoding the ComX protein of SEQ ID NO:12, or is a variant of SEQ ID NO:11 encoding a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:12. In a particular embodiment, said *comX* gene is used when the *Lactococcus* strain in step a) is a *Lactococcus piscium* strain.

In a particular embodiment, said *comX* gene has the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 or SEQ ID NO:17, any sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO:13 or SEQ ID NO:15 or SEQ ID NO:17 or a variant of SEQ ID NO:13 or SEQ ID NO:15 or SEQ ID NO:17 encoding respectively the ComX protein of SEQ ID NO:14 or SEQ ID NO:16 or SEQ ID NO:18 or a variant of SEQ ID NO:13 or SEQ ID NO:15 or SEQ ID NO:17 encoding respectively a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:14 or SEQ ID NO:16 or SEQ ID NO:18. In a particular embodiment, said *comX* gene is used when the *Lactococcus* strain in step a) is a *Lactococcus garvieae* strain.

In some embodiments, said *comX* gene has the nucleotide sequence of SEQ ID NO:19 or has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO:19 or is a variant of SEQ ID NO:19 encoding the ComX protein of SEQ ID NO:20, or is a variant of SEQ ID NO:19 encoding a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:20. In a particular embodiment, said *comX* gene is used when the *Lactococcus* strain in step a) is a *Lactococcus fujiensis* strain.

In some embodiments, said *comX* gene has the nucleotide sequence of SEQ ID NO:21 or has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO:21 or is a variant of SEQ ID NO:21 encoding the ComX protein of SEQ ID NO:22, or is a variant of SEQ ID NO:21 encoding a functional ComX protein having at least 90% identity or at least 90% similarity to a ComX protein of SEQ ID NO:22. In a particular embodiment, said *comX* gene is used when the *Lactococcus* strain in step a) is a *Lactococcus chungangensis* strain.

By way of example and for the avoidance of doubt, in particular embodiments, where a *comX* gene is specified as having a particular nucleotide sequence, it is understood that the *comX* gene comprises said nucleotide sequence. In particular other embodiments, where a *comX* gene is specified as having a particular nucleotide sequence, it is understood that the *comX* gene consists of said nucleotide sequence.

In some embodiments, variants as defined herein of *comX* genes are selected from the list of DNA sequences disclosed in Table 1 below:

Strain	Accession number	Position of *comX*, from start to stop
Lactococcus lactis AI06	CP009472.1	From 2260881 to 2261372 (reverse)
Lactococcus lactis Bpl1	JRFX01000055.1	From 34668 to 35159 (forward)
Lactococcus lactis Ll1596	LDEK01000015.1	From 33401 to 33892 (forward)
Lactococcus lactis subsp. *cremoris* A17	JQIC01000009.1	From 6445 to 6936 (reverse)
Lactococcus lactis subsp. *cremoris* A76	CP003132.1	From 2293232 to 2293723 (reverse)
Lactococcus lactis subsp. *cremoris* AM2	LITE01000081.1	From 9954 to 10444 (forward)
Lactococcus lactis subsp. *cremoris* B40	LITC01000320.1	From 10186 to 10677 (forward)
Lactococcus lactis subsp. *cremoris* DPC6856	LAVW01000168.1	From 445 to 936 (reverse)
Lactococcus lactis subsp. *cremoris* GE214	AZSI01000020.1	From 186 to 677 (reverse)
Lactococcus lactis subsp. *cremoris* HP	JAUH01000192.1	From 40 to 531 (reverse)
Lactococcus lactis subsp. *cremoris* IBB477	JMMZ01000035.1	From 92323 to 92814 (reverse)
Lactococcus lactis subsp. *cremoris* KW10	LIYF01000023.1	From 40421 to 40912 (forward)
Lactococcus lactis subsp. *cremoris* KW2	CP004884.1	From 2276371 to 2276862 (reverse)
Lactococcus lactis subsp. *cremoris* LMG6897	LISZ01000238.1	From 10034 to 10525 (forward)
Lactococcus lactis subsp. *cremoris* Mast36	JZUI01000076.1	From 310 to 801 (reverse)
Lactococcus lactis subsp. *cremoris* MG1363	AM406671.1	From 2376782 to 2377273 (reverse)
Lactococcus lactis subsp. *cremoris* NBRC 100676	BCVK01000073.1	From 9879 to 10370 (forward)
Lactococcus lactis subsp. *cremoris* NZ9000	CP002094.1	From 2377598 to 2378089 (reverse)
Lactococcus lactis subsp. *cremoris* SK11	CP000425.1	From 2283008 to 2283498 (reverse)
Lactococcus lactis subsp. *cremoris* TIFN1	ASXF01000005.1	From 5621 to 6112 (forward)
Lactococcus lactis subsp. *cremoris* TIFN3	ATBE01000400.1	From 431 to 922 (reverse)
Lactococcus lactis subsp. *cremoris* TIFN5	ATBC01000090.1	From 315 to 809 (reverse)
Lactococcus lactis subsp. *cremoris* TIFN6	ATBB01000278.1	From 265 to 756 (forward)
Lactococcus lactis subsp. *cremoris* TIFN7	ATBA01000081.1	From 5620 to 6111 (forward)
Lactococcus lactis subsp. *cremoris* UC509.9	CP003157.1	From 2107522 to 2108013 (reverse)
Lactococcus lactis subsp. *cremoris* V4	LIYG01000005.1	From 8625 to 9116 (forward)
Lactococcus lactis subsp. *hordniae* NBRC 100931	BCVL01000030.1	From 70 to 561 (reverse)
Lactococcus lactis subsp. *lactis* 1AA59	AZQT01000035.1	From 118 to 609 (reverse)
Lactococcus lactis subsp. *lactis* 511	JNLP01000001.1	From 1703029 to 1703520 (reverse)
Lactococcus lactis subsp. *lactis* A12	LT599049.1	From 2415707 to 2416198 (reverse)
Lactococcus lactis subsp. *lactis* ATCC 19435	LKLC01000004.1	From 32310 to 32801 (forward)
Lactococcus lactis subsp. *lactis* bv. *diacetylactis* DRA4	LIWD01000119.1	From 147 to 638 (reverse)
Lactococcus lactis subsp. *lactis* CV56	CP002365.1	From 2213300 to 2213791 (reverse)
Lactococcus lactis subsp. *lactis* DPC6853	LAVD01000101.1	From 544 to 1035 (reverse)
Lactococcus lactis subsp. *lactis* E34	LKLD01000014.1	From 197 to 688 (reverse)
Lactococcus lactis subsp. *lactis* Il1403	AE005176.1	From 2223528 to 2224019 (reverse)
Lactococcus lactis subsp. *lactis* IO-1 DNA	AP012281.1	From 2287126 to 2287617 (reverse)
Lactococcus lactis subsp. *lactis* JCM 7638	BBAP01000017.1	From 34164 to 34656 (forward)
Lactococcus lactis subsp. *lactis* K231	LKLE01000041.1	From 32159 to 32650 (forward)
Lactococcus lactis subsp. *lactis* K337	LKLF01000041.1	From 34909 to 35400 (forward)
Lactococcus lactis subsp. *lactis* KF134	LKLJ01000010.1	From 34939 to 35430 (forward)
Lactococcus lactis subsp. *lactis* KF147	CP001834.1	From 2446402 to 2446893 (reverse)
Lactococcus lactis subsp. *lactis* KF201	LKLM01000024.1	From 28747 to 29238 (forward)
Lactococcus lactis subsp. *lactis* KF24	LKLH01000011.1	From 34116 to 34607 (forward)
Lactococcus lactis subsp. *lactis* KF282	LKLN01000033.1	From 170 to 661 (reverse)
Lactococcus lactis subsp. *lactis* KLDS 4.0325	CP006766.1	From 2407603 to 2408094 (reverse)
Lactococcus lactis subsp. *lactis* LMG 7760	JQCM01000018.1	From 37736 to 38227 (forward)
Lactococcus lactis subsp. *lactis* LMG8526	LKLQ01000046.1	From 38499 to 38993 (forward)
Lactococcus lactis subsp. *lactis* NCDO 2118	CP009054.1	From 2402923 to 2403414 (reverse)
Lactococcus lactis subsp. *lactis* S0	CP010050.1	From 2359456 to 2359947 (reverse)
Lactococcus lactis subsp. *lactis* UC317	LKLY01000004.1	From 36130 to 36621 (forward)
Lactococcus lactis WG2	LXWJ01000007.1	From 37921 to 38412 (forward)
Lactococcus raffinolactis NBRC 100932	BCVN01000102.1	From 139 to 617 (forward)
Lactococcus piscium CNCM I-4031	FLZT01000001.1	From 149 to 628 (forward)
Lactococcus piscium MKFS47	LN774769.1	From 1708720 to 1709199 (forward)
Lactococcus garvieae 122061	AP017373.1	From 1356405 to 1356890 (forward)
Lactococcus garvieae 8831	AFCD01000005.1	From 510 to 995 (forward)

Lactococcus garvieae Lg-ilsanpaik-gs201105	JPUJ01000002.1	From 180817 to 181302 (reverse)
Lactococcus garvieae LG9	AGQY01000137.1	From 5631 to 6116 (reverse)
Lactococcus garvieae M79	FOTJ01000023.1	From 3224 to 3709 (forward)
Lactococcus garvieae NBRC 100934	BBJW01000010.1	From 105946 to 106431 (reverse)
Lactococcus garvieae PAQ102015-99	LXWL01000009.1	From 238437 to 238922 (reverse)
Lactococcus garvieae TB25	AGQX01000090.1	From 28088 to 28573 (reverse)
Lactococcus garvieae TRF1	AVFE01000015.1	From 42141 to 42626 (reverse)

Table 1

As used herein a *comX* gene is understood to be a gene that encodes a functional ComX protein in the strain where it is expressed. By "*functional ComX protein*" it is meant a protein which induces or is able to induce the expression of genes regulated by the Com-box, and at least one of the late competence genes selected from *comEA*, *comFA*, *comGA*, *dprA*, *coiA*, *ssbA*, *radA*, *radC*, *recA,* and *recX*.

The ComX protein may have the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22.

In some embodiments, the ComX protein may have the amino acid sequence of SEQ ID NO:2, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:2. In a particular embodiment, said ComX protein is used when the *Lactococcus* strain in step a) is a *Lactococcus lactis* subsp. *lactis* strain.

In some embodiments, the ComX protein may have the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least

95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6. In a particular embodiment, said ComX protein is used when the *Lactococcus* strain in step a) is a *Lactococcus lactis* subsp. *cremoris* strain.

In some embodiments, the ComX protein may have the amino acid sequence of SEQ ID NO:8, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:8 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:8. In a particular embodiment, said ComX protein is used when the *Lactococcus* strain in step a) is a *Lactococcus raffinolactis* strain.

In some embodiments, the ComX protein may have the amino acid sequence of SEQ ID NO:10, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:10 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:10. In a particular embodiment, said ComX protein is used when the *Lactococcus* strain in step a) is a *Lactococcus plantarum* strain.

In some embodiments, the ComX protein may have the amino acid sequence of SEQ ID NO:12, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:12 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:12. In a particular embodiment, said ComX protein is used when the *Lactococcus* strain in step a) is a *Lactococcus piscium* strain.

In some embodiments, the ComX protein may have the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16 or SEQ ID NO:18, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16 or SEQ ID NO:18 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:14, SEQ ID NO:16 or SEQ ID

NO:18. In a particular embodiment, said ComX protein is used when the *Lactococcus* strain in step a) is a *Lactococcus garvieae* strain.

In some embodiments, the ComX protein may have the amino acid sequence of SEQ ID NO:20, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:20 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:20. In a particular embodiment, said ComX protein is used when the *Lactococcus* strain in step a) is a *Lactococcus fujiensis* strain.

In some embodiments, the ComX protein may have the amino acid sequence of SEQ ID NO:22, or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:22 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similarity to the amino acid sequence of SEQ ID NO:22. In a particular embodiment, said ComX protein is used when the *Lactococcus* strain in step a) is a *Lactococcus chungangensis* strain.

According to the invention, when a ComX protein is defined by its amino acid sequence having a percentage of identity or percentage of similarity to a specific SEQ ID, said ComX protein is a functional ComX protein as defined herein.

By way of example and for the avoidance of doubt, in particular embodiments, where a ComX protein is specified as having a particular amino acid sequence, it is understood that the ComX protein comprises said amino acid sequence. In particular other embodiments, where a ComX protein is specified as having a particular amino acid sequence, it is understood that the ComX protein consists of said amino acid sequence.

In some embodiments, ComX proteins having percentage of identity or percentage of similarity as defined herein are selected from the list of protein sequences derived, after translation, from the list of DNA sequences disclosed in Table 1 above.

Preferably, reference to a sequence which has a percentage identity or similarity to any one of the SEQ ID NOs detailed herein refers to a sequence which has the stated percent identity or similarity with the SEQ ID NO referred to, over the entire length of the two sequences. Percentage (%) sequence identity is defined as the percentage of amino acids or nucleotides in a candidate sequence that are identical to the amino acids or nucleotides in a reference

sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Percentage (%) sequence similarity is defined as the percentage of amino acids in a candidate sequence that are similar to the amino acids in a reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence similarity. Similarity between amino acids is based on established amino acid substitution matrices such as the PAM series (Point Accepted Mutation; e.g. PAM30, PAM70, and PAM250) or the BLOSUM series (BLOck SUbstitution Matrix; e.g. BLOSUM45, BLOSUM50, BLOSUM62, BLOSUM80, and BLOSUM90). Alignment for purposes of determining percent sequence identity or similarity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as CLUSTALW, CLUSTALX, CLUSTAL Omega, BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. In a particular embodiment, similarity between amino acids is determined using the BLASTp software with the BLOSUM62 matrix. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared, or gap penalties to be introduced, can be determined by known methods.

In a particular embodiment, when the modulation in step b) results from an exogenous *comX* gene, said exogenous *comX* gene is (obtained) from a strain of the same species, in particular of the same subspecies, as the strain provided in step a). In any case, the exogenous *comX* gene needs to be functional, in particular needs to encode a functional ComX protein, as defined herein in the strain provided in step a).

Exogenous DNA polynucleotide

The method of the present invention comprises the step of contacting the strain of step b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA into the genome of said strain [step c].

As used herein the term "*exogenous DNA polynucleotide*" refers to a DNA polynucleotide that is brought into the cytoplasm of said strain, in order to be integrated into the genome of said strain (target sequence).

In a particular embodiment, the method comprises carrying out step (b) [ComX modulation] and then carrying out step (c) [contact with the exogenous DNA polynucleotide] [*i.e.,* that step (c) is carried out on a strain obtained following step (b)]. Thus, the method comprising the steps of:

(a) providing a strain of the *Lactococcus* genus, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain obtained in step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

In another embodiment, the method comprises carrying out simultaneously step (b) [ComX modulation] and step (c) [contact with the exogenous DNA polynucleotide]. This option is appropriate when the ComX modulation is the result of the expression of the endogenous *comX* gene or of the increase of the expression of the endogenous *comX* gene of said strain. Thus, the method comprising the steps of:

(a) providing a strain of the *Lactococcus* genus, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome;

wherein step (b) and step (c) are carried out simultaneously.

In a particular embodiment, the sequence of the exogenous DNA polynucleotide used in step c) share some similarities or identities with the genome of the *Lactococcus* strain to be transformed (of step a). In a particular embodiment, the exogenous DNA polynucleotide used in step c) is designed such that its 5' part and its 3' part are identical or highly similar to parts of the genome of the *Lactococcus* strain to be transformed (of step a), while its central part can be different from the genome of the *Lactococcus* strain to be transformed (of step a). The high similarity of the arms with the regions surrounding the target sequence can be determined by the person skilled in the art using common general knowledge, in particular by reference to homologous recombination.

Thus, to replace a target sequence by a mutated sequence or a truncated sequence or a supplementary sequence in the genome of the *Lactococcus* strain to be transformed (of step a), the exogenous DNA polynucleotide used in step c) is designed such that:

- its 5' part is identical or highly similar to the region of the genome of the *Lactococcus* strain to be transformed which is on one side of the target sequence;
- its central part contains the replacing sequence (*i.e.,* the mutated sequence or the truncated sequence or the supplementary sequence); and
- its 3' part is identical or highly similar to the region of the genome of the *Lactococcus* strain to be transformed which is on the other side of the target sequence.

The 5' part and 3' part are long enough to ensure efficient recombination. In a particular embodiment, each of the 5' part and 3' part is from 0.5 to 5 kb in length. The size of the arms can be determined by the person skilled in the art using common general knowledge, in particular by reference to homologous recombination.

In a particular embodiment, the exogenous DNA polynucleotide used in step c) is (obtained) from a strain of the *Lactococcus* genus.

In a particular embodiment, said exogenous DNA polynucleotide used in step (c) is (obtained) from a strain of the same species, in particular of the same subspecies, as the strain provided in step (a).

In a particular embodiment, the exogenous DNA polynucleotide used in step c) is from a strain of the *Lactococcus lactis* species. In a particular embodiment, the exogenous DNA polynucleotide used in step c) is from a strain of the same *Lactococcus lactis* subspecies as the strain provided in step a). In a particular embodiment, the exogenous DNA polynucleotide used in step c) is from a strain of a *Lactococcus lactis* subspecies which is different from the strain provided in step a).

In a particular embodiment, the exogenous DNA polynucleotide used in step c) is from a strain of the *Lactococcus raffinolactis* species

The exogenous DNA polynucleotide may encode part of a gene sequence, a gene sequence, or a plurality of gene sequences. The gene sequence may be operably linked to transcription regulator(s). In a particular embodiment, the exogenous DNA polynucleotide is linear. The exogenous DNA polynucleotide may be designed to facilitate its incorporation within the genome of the *L. lactis* strain by homologous recombination (e.g. the exogenous DNA polynucleotide may comprise one or more recombination arms). The exogenous DNA polynucleotide may be a single stranded linear DNA.

The exogenous DNA polynucleotide, when incorporated into the genome of said *Lactococcus* strain leads to genetic modification of the strain such as gene replacement (to add or to remove a mutation), gene addition (to add a new gene or to duplicate an existing gene), gene deletion (to remove part or the totality of a gene), modification of non-coding region (to modulate

expression of a gene). Typically, the exogenous DNA polynucleotide, when incorporated into the genome of said *Lactococcus* strain confers an interesting or useful phenotype, e.g. modified kinetic of acidification, improved resistance to bacteriophage, modified capability to grow in milk, modified texturing properties, improved safety of the strain. For example, improved bacteriophage resistance could be achieved by incorporating genes coding for a restriction/modification system into the strain genome or by introducing a mutation or a deletion into the *pip* gene.

As an example, growth of a *L. lactis* strain in milk could be improved by inserting into the chromosome the *prtP* and *prtM* genes that allow casein hydrolysis and better nitrogen nutrition; alternatively, these genes could be inactivated to reduced milk proteolysis in cheese. *hisDC* and *tyrDC* are genes known to be responsible for biogenic amine production (histamine and tyramine, respectively) in a diversity of lactic acid bacteria; disruption or mutation of these genes could help to prevent safety issues related to cheese consumption.

In a particular embodiment, the exogenous DNA polynucleotide has a minimal size selected from the group consisting of 100 bp, 200 bp, 500 bp, 1 kb, 2 kb and 5 kb, and a maximal size selected from the group consisting of 500 bp, 1 kb, 2 kb, 5 kb, 10 kb, 20 kb and 50 kb. In a particular embodiment, the size of the exogenous DNA polynucleotide may be between 100 bp and 50 kb, more preferably between 500 bp to 20 kb, even more preferably between 1 kb to 10 kb.

The concentration of exogenous DNA polynucleotide in the medium of step (c) may be between 0.5 mg/L and 1 g/L, preferably between 1 mg/L and 500 mg/L, more preferably between 5 mg/L and 100 mg/L, even more preferably between 10 mg/L and 50 mg/L of medium.

Selection of transformed strains

The method of the present invention comprises the step of selecting a strain which has integrated the exogenous DNA polynucleotide into its genome [step d)].

If needed, selection is carried out on some cells of colonies that have been previously obtained by multiplying, in the appropriate medium, cells obtained at the end of step c) (or at the end of the simultaneous steps b) and c), when appropriate).

Various methods for the selection of transformed bacteria are well known in the art (see, e.g. Sambrook *et al.*) and may be routinely applied by the person skilled in the art, such as PCR, DNA sequencing…

For example, when the exogenous DNA polynucleotide used in step c) provides a particular phenotype that the *Lactococcus* strain of step a) does not display (either a new phenotype or restoring a lost phenotype), it is possible to select strains which have integrated the exogenous DNA polynucleotide into their genome by selecting strains expressing the phenotype. This is the case for a strain having integrated in its genome an exogenous DNA polynucleotide mutated for the *pip* gene (that provides resistance to some bacteriophages).

For example, when the exogenous DNA polynucleotide used in step c) leads once integrated to a loss of a phenotype initially displayed by the *Lactococcus* strain of step a), it is possible to select strains which have integrated the exogenous DNA polynucleotide into their genome by selecting strains which do not diplay the phenotype any more. This is the case for an exogenous DNA polynucleotide bearing a mutated *hisDC* or *tyrDC* gene, which suppresses or decreases the production of histamine or tyramine, respectively.

As a particular example, the exogenous DNA polynucleotide may bear an antibiotic resistance gene. Accordingly, a *Lactococcus* strain which has integrated the exogenous DNA polynucleotide into its genome may be selected by plating onto a medium comprising said antibiotic. Only strains that express the appropriate antibiotic resistance gene, as a result of a successful transformation with the exogenous DNA polynucleotide, will multiply.

Growth conditions

As described in Example 3, a positive effect on natural competence induction in *L. lactis* strains was observed when cells were pre-cultured in a complex medium before transferring the cells to a chemically defined medium (Figure 3).

Accordingly, in some embodiments the medium of step (c) is a chemically defined medium. As used herein, the term “chemically defined medium” (CDM) refers to a medium for which the exact chemical composition is known. Preferably, the CDM may have the composition of the CDM set out in Sissler *et al.* (1999, Proc Natl Acad Sci USA 96:8985-8990). Thus, in an embodiment, the chemically defined medium (CDM) comprises 0.5 g/L NH_4Cl, 9.0 g/L KH_2PO_4, 7.5 g/L K_2HPO_4, 0.2 g/L $MgCl_2$, 5 mg/L $FeCl_2$, 50 mg/L $CaCl_2$, 5 mg/L $ZnSO_4$, 2.5 mg/L $CoCl_2$, 0.05 g/L tyrosine, 0.1 g/L asparagine, 0.1 g/L cysteine, 0.1 g/L glutamine, 0.1 g/L isoleucine, 0.1 g/L leucine, 0.1 g/L methionine, 0.1 g/L tryptophan, 0.1 g/L valine, 0.1 g/L histidine, 0.2 g/L arginine, 0.2 g/L glycine, 0.2 g/L lysine, 0.2 g/L phenylalanine, 0.2 g/L threonine, 0.3 g/L alanine, 0.3 g/L proline, 0.3 g/L serine, 10 mg/L paraaminobenzoic acid, 10 mg/L biotin, 1 mg/L folic acid, 1 mg/L nicotinic acid, 1 mg/L panthotenic acid, 1 mg/L riboflavin, 1 mg/L thiamine, 2 mg/L pyridoxine, 1 mg/L cyanocobalamin, 5 mg/L orotic acid, 5 mg/L 2-deoxythymidine, 5 mg/L

inosine, 2.5 mg/L *dl*-6,8-thioctic acid, 5 mg/L pyridoxamine, 10 mg/L adenine, 10 mg/L guanine, 10 mg/L uracil, 10 mg/L xanthine, and 5 g/L glucose..

In some embodiments, prior to step (c) said strain is incubated in a pre-culture medium, preferably wherein the pre-culture medium is a complex medium, more preferably wherein the pre-culture medium is M17G (i.e., the M17 medium supplemented with glucose) or THBG (i.e., the THB medium supplemented with glucose).

The complex medium may be Todd Hewitt broth (THB) (Todd and Hewitt, 1932; Updyke and Nickle, 1954) or M17 broth (Terzaghi and Sandine, 1975). THB may comprise 500 g/L beef heart infusion, 20 g/L peptic digest of animal tissue, 2 g/L dextrose, 2 g/L sodium chloride, 0.4 g/L sodium phosphate, 2.5 g/L sodium carbonate. M17 broth may comprise: 0.5 g/L ascorbic acid, 5 g/L lactose, 0.25 g/L magnesium sulfate, 5 g/L meat extract, 2.5 g/L meat peptone (peptic), 19 g/L sodium glycerophosphate, 5 g/L soya peptone (papainic), 2.5 g/L tryptone, 2.5 g/L yeast extract.

Method for identifying strains transformable by natural competence

In another aspect, the present invention relates to a method for identifying a strain of the *Lactococcus* genus which is transformable through natural competence. Said method comprises the following steps:

(a) providing a strain of the *Lactococcus* genus;

(b) transforming said strain with a plasmid expressing a *comX* gene having at least 90% identity, preferably having 100% identity, to the endogenous *comX* gene of said strain;

(c) contacting said strain obtained in step (b) with an exogenous marker DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) determining the rate of recombination events;

wherein a rate of at least 1 x 10^{-6} transformants per µg of DNA is indicative of a strain which is transformable through natural competence.

The term "*rate of recombination events*" may be used interchangeably with the term "transformation rate". The rate of recombination events is calculated by determining the ratio of the number of cells having integrated the exogenous marker DNA polynucleotide over the total number of viable cells. A rate of at least 10^{-6} was selected as a threshold, based on the observation that the level of spontaneous mutation in lactococci is less than 10^{-6}, typically

around 10^{-7} mutants per µg of DNA [spontaneous means with no *comX* expression or overexpression].

By "at least 90% identity to the endogenous *comX* gene of said strain", it is meant - as particular embodiments of the method - at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity. In a particular embodiment, said *comX* gene has 100% identity to the endogenous *comX* gene of said strain.

In a particular embodiment, said method is implemented with a strain of the *Lactococcus* genus selected from the group consisting of *Lactococcus lactis, Lactococcus raffinolactis, Lactococcus plantarum, Lactococcus piscium, Lactococcus garivieae, Lactococcus fujiensis* and *Lactococcus chungangensis.*

In a particular embodiment, said method is implemented with a strain of the *Lactococcus lactis* species. Said method comprises the following steps:

(a) providing a strain of the *Lactococcus lactis* species;

(b) transforming said strain with a plasmid expressing a *comX* gene having at least 90% identity to the polynucleotide sequence of SEQ ID NO:1, 3 or 5;

(c) contacting said strain obtained in step (b) with an exogenous marker DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) determining the rate of recombination events;

wherein a rate of at least 1 x 10^{-6} transformants per µg of DNA is indicative of a strain of the *Lactococcus lactis* species which is transformable through natural competence.

In a particular embodiment, said method is implemented with a strain of the *Lactococcus raffinolactis* species. Said method comprises the following steps:

(a) providing a strain of the *Lactococcus raffinolactis* species;

(b) transforming said strain with a plasmid expressing a *comX* gene having at least 90% identity to the polynucleotide sequence of SEQ ID NO:7;

(c) contacting said strain obtained in step (b) with an exogenous marker DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) determining the rate of recombination events;

wherein a rate of at least 1 x 10^{-6} transformants per µg of DNA is indicative of a strain of the *Lactococcus lactis* species which is transformable through natural competence.

In some embodiments, the *comX* gene is from a strain of the same species, in particular of the same subspecies, as the strain provided in step a). In some embodiments, the *comX* gene is identical (100% identity) to the polynucleotide sequence of the endogenous *comX* gene of the strain of step a).

In some embodiments, when the strain of step a) is a *Lactococcus lactis* subsp. *lactis* strain, the *comX* gene has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polynucleotide sequence of SEQ ID NO:1.

In some embodiments, when the strain of step a) is a *Lactococcus lactis* subsp. *cremoris* strain the *comX* gene has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polynucleotide sequence of SEQ ID NO:3 or SEQ ID NO:5.

In some embodiments, when the strain of step a) is a *Lactococcus raffinolactis* strain the *comX* gene has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polynucleotide sequence of SEQ ID NO:7.

In some embodiments, when the strain of step a) is a *Lactococcus plantarum* strain the *comX* gene has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polynucleotide sequence of SEQ ID NO:9.

In some embodiments, when the strain of step a) is a *Lactococcus piscium* strain the *comX* gene has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polynucleotide sequence of SEQ ID NO:11.

In some embodiments, when the strain of step a) is a *Lactococcus garvieae* strain the *comX* gene has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polynucleotide sequence of SEQ ID NO:13, SEQ ID NO:15, or SEQ ID NO:17.

In some embodiments, when the strain of step a) is a *Lactococcus fujiensis* strain the *comX* gene has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at

least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polynucleotide sequence of SEQ ID NO:19.

In some embodiments, when the strain of step a) is a *Lactococcus chungangensis* strain the *comX* gene has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polynucleotide sequence of SEQ ID NO:21.

It is preferable to use, as an exogenous marker DNA polynucleotide, a polynucleotide bearing a gene which is initially not present in the *Lactococcus* strain of step a) [even as a mutated version]. This would avoid that during step c) the *Lactococcus* strain acquires a functional gene by other means than natural competence, e.g. by spontaneous mutation of its genome.

As an example, the exogenous marker DNA polynucleotide bears a gene encoding a luciferase gene. Accordingly, a *Lactococcus* strain which has integrated the exogenous DNA polynucleotide into its genome may be selected for expression of the luciferase. Only strains that express the luciferase gene (i.e., integrated) will be detectable by bioluminescence.

As another example, the exogenous marker DNA polynucleotide bears an antibiotic resistance gene. Accordingly, a *Lactococcus* strain which has integrated the exogenous DNA polynucleotide into its genome may be selected by plating the cells onto a medium comprising said antibiotic.

An example of a method for identifying a strain of the *Lactococcus* genus which is transformable through natural competence according to the present invention (Assay A) may be performed using the following steps:

i) Providing a strain of the *Lactococcus* genus, in particular of the *Lactococcus lactis* species.

ii) Transforming said strain with a plasmid expressing a *comX* gene having at least 90% identity, preferably having 100% identity to the endogenous *comX* gene of said strain (e.g. the pGhP32comX_{MG} plasmid of Materials and Methods).

iii) Pre-culturing the transformed strain overnight in a complex medium supplemented with glucose (e.g. M17G) at 30 °C.

iv) Diluting about 1.5 mL of the pre-culture in about 8.5 mL of fresh medium.

v) After about 2 hours further growth at 30 °C, washing the cells twice with distilled water and adjusting the OD_{600} to 0.05 in a chemically defined medium (e.g. CDM) containing 5 µg mL^{-1} erythromycin and an osmo-stabilizer (e.g. 5 % [v/v] glycerol or 5 % [w/v] mannitol).

vi) Adding 5 µg of exogenous DNA polynucleotide bearing an antibiotic resistance gene to 300 µl of the culture medium (e.g. the 3.7 kb PCR product generated from the pGEMrpsL plasmid as described in Materials and Methods).

vii) Incubating the resulting culture for about 6 hours at 30 °C.

viii) Plating the cells onto agar plates comprising the complex medium supplemented with glucose (e.g. M17G) and appropriate antibiotic (i.e. corresponding to the antibiotic resistance gene of the exogenous DNA polynucleotide) and incubating for about 48 hours.

ix) Counting the colony forming units (CFU) and determining the transformation rate, wherein a transformation rate of at least 1 x 10^{-6} transformants per µg of DNA is indicative of a strain which is transformable through natural competence.

The transformation rate may be calculated as the number of antibiotic-resistance CFU mL^{-1} divided by the total number of viable CFU mL^{-1}.

Various preferred features and embodiments of the present invention will now be described by way of non-limiting examples.

EXAMPLES

Example 1: Induction of the *comGA* promoter by constitutive *comX* expression in various strains of the *Lactococcus* species

a) in Lactococcus lactis *subsp.* cremoris *strains (MG1363 and KW2)*

To test the ability of ComX to induce the late competence genes in *Lactococcus lactis* subsp. *cremoris* strains, a constitutive *comX* expression plasmid (pGhP32comX_{MG}) was created by cloning the *comX* gene from strain MG1363, under the control of the lactococcal P_{32} promoter on the thermosensitive plasmid pG^{+}host9. The latter was introduced in strain KW2 that contains a chromosomally-encoded $P_{comGA[MG]}$-*luxAB* transcriptional fusion (BLD101). The promoter of the late competence gene *comGA* (P_{comGA}) contains a putative ComX-binding motif and is used here as proxy for competence activation in the $ComX^{+}$ strain.

As alternative for more resistant strains to electro-transformation, and subsequently to chromosome integration, a portable luminescent reporter system was also constructed. This replicative plasmid carries the luminescent reporter $P_{comGA[MG]}$-*luc* with the P_{32}-$comX_{MG}$ cassette. The pGhP32comX_{MG}-$P_{comGA[MG]}$-*luc* plasmid was transformed in strain MG1363.

Specific $P_{comGA[MG]}$-*luc/luxAB* activities were monitored for the different strains constructed. The luminescent assays were performed in rich (M17G) and/or CDM media comparing the luciferase activity between the overexpressing *comX* strain and its related negative control (no additional *comX* copy).

In the KW2 strain containing the $P_{comGA[MG]}$-*luxAB* reporter as mono-copy in their chromosome, specific luciferase activity was observed for KW2 containing the P_{32}-*comX* cassette allowing the constitutive production of ComX. This confirms that *comX* expression can be carried out in various *L. lactis* subsp. *cremoris* strains using an exogenous *comX* gene obtained from the same strain or from a strain of the same subspecies. Eight recombinant clones of the KW2 ComX$^+$ reporter strain were randomly selected and their specific luciferase activity was monitored in CDM growth conditions. This medium was chosen because it was shown to be permissive for competence development in various streptococcal species. To ensure reproducibility of the assay, exponentially-growing cells in complex medium (M17 conditions) were washed and inoculated in fresh CDM before starting the experiment. As expected, all tested ComX$^+$ clones (cl01 to cl08) displayed between 10^1-and 10^4-fold higher specific luciferase (Lux) activity than the control strain carrying the empty vector (Figure 2A and 2B).

Similar results were obtained with the portable luminescent reporter systems in MG1363 (Figure 2C).

These results strongly suggest that, in the *L. lactis* subsp. *cremoris* strains MG1363 and KW2, ComX induces the *comG* operon. Additionally, these observations validate these reporter fusions (both chromosomal and plasmid-borne) as a tool to identify conditions capable to activate the *comG*-operon which is essential to natural transformation.

b) in a L. lactis *subsp.* lactis *strain (IL1403)*

A constitutive *comX* expression plasmid (pGhP32comX_{IO}) was created by cloning the *comX* gene from strain IO-1, under the control of the lactococcal P_{32} promoter on the thermosensitive plasmid pG$^+$host9. A portable luminescent reporter system was also constructed; this replicative plasmid carries the luminescent reporter $P_{comGA[IO]}$-*luc* with the P_{32}-$comX_{IO}$ cassette. The promoter of the late competence gene *comGA* (P_{comGA}) contains a putative ComX-binding motif and is used here as proxy for competence activation in the ComX$^+$ strain.

This replicative plasmid pGhP32comX_{IO}-$P_{comGA[IO]}$-*luc* was transformed in strain IL1403 and specific $P_{comGA[IO]}$-*luc* activities were monitored. One of the IL1403 transformants produced specific $P_{comGA[IO]}$-*luc* activities confirming that ComX induces the *comG* operon (Figure 2D).

Example 2: Analysis of essential late *com* genes present in *L. lactis* genomes

Among *L. lactis* strains, genomic variability was previously investigated for *comX* and *dprA* alleles (Wydau *et al.*, 2006). While all strains (31/31) display a complete version of *comX*, the *dprA* content is variable among subspecies: 50 % of the *lactis* strains (10/20) contain nonsense mutations in *dprA* while all *cremoris* strains (11/11) harbor an intact and potentially functional *dprA* gene.

Since *dprA* is hypothesized to be important in the natural competence mechanism, its integrity in *L. lactis* strains prompted us to further analyze the minimal set of late *com* genes (17 candidate genes including *comX;* Figure 1) in the genomes of 3 subsp. *cremoris* strains and 1 subsp. *lactis* strain which are publicly available (strains MG1363, SK11, KW2 and IL1403). This *in silico* analysis reveals that the genome of SK11 contains a high number of pseudogenes in key competence genes (between 5 and 8 incomplete late *com* genes) due to transposon insertion or frameshifting events (nucleotide(s) insertion or deletion). In particular, the presence of transposable elements in *comGA* and/or *comEC* genes, which are respectively essential for pilus assembly and DNA transport, strongly suggests that natural transformation is no more functional in those strains. Although the set of full-length competence genes in the laboratory strain MG1363 is larger, mutations in *comEC* (nucleotide insertion) and *coiA* (nonsense mutation) probably impair its ability to transform DNA by competence (Wegmann *et al.*, 2007). Those mutations were also found in the genome of its isogenic derivative NZ9000, which strongly suggests that they do not result from DNA sequencing errors. As far as the *L. lactis* subsp. *lactis* IL1403 strain is concerned, its *dprA* gene contains nonsense mutations probably impairing its ability to transform DNA by competence. In contrast, strain KW2 of plant origin (corn fermentation) contains the whole set of known essential late genes required to fulfil natural DNA transformation, making it the best candidate to further study the functionality of competence in the *cremoris* subspecies. Two other strains from our collection, *L. lactis* subsp. *lactis* SL12651 and SL12653, were also found to contain the whole set of known essential late genes (Figure 1).

Example 3: Effect of growth conditions on ComX activation

We investigated the effect of pre-culturing and culturing conditions (M17G, THBG, and CDM) on the activation of the reporter fusion in the ComX$^+$ strain. For this purpose, clone 02 (Figure 2A) was selected since it exhibits the strongest Lux activity. Interestingly, more than a 20-fold variation in the maximum Lux activity was dependent on the pre- and culturing medium which was used (Figure 3). Particularly, a positive impact of the transition of pre-culture cells from a

complex medium to a defined medium was observed. The highest specific Lux activity (~3 × 10^6 RLU OD_{600}^{-1}) was obtained for a switch from M17G to CDM, followed by THBG to CDM, while all other combinations gave lower activities (between ~ 1.5 × and 5.5 × 10^5 RLU OD_{600}^{-1}). This indicates that first a chemically defined medium is superior for maximizing activation of late *com* genes of *L. lactis* KW2 than complex rich media, but also that the switch from complex medium (e.g. M17G or THBG) to defined medium is critical.

Together, these results show that ComX is functional in strain KW2 when it is constitutively produced (i.e. expressed) and that growth conditions have a significant impact on the activation of late *com* genes.

Example 4: Constitutive *comX* expression induces natural transformation

a) Acquisition of single mutations in the KW2 genome from exogenous DNA

We first tested the transfer of single point mutations in the chromosome of the $ComX^+$ KW2 strain. The transforming PCR fragments used encompass the mutated *rpsL* allele of a spontaneous streptomycin-resistant (Str^r) clone of *L. lactis* subsp. *cremoris* MG1363 (*strA1* allele, also called *rpsL**). This mutated allele bears an A→T substitution at position 167 [resulting in the altered ribosomal protein S12 with mutation K56I] as compared to the sequence of the wild-type, streptomycin-sensitive MG1363. In addition to this mutation, the two *rpsL* alleles differ by a silent nucleotide substitution at position 39 (T→G). The sequence of the *rpsL* (wild-type) and *rpsL** (conferring streptomycin resistance) alleles are disclosed respectively as SEQ ID NO:23 and NO:24 (Figure 4A). Independently of these two substitutions located at positions 39 and 167, the *rpsL* alleles of KW2 and MG1363 differ by a nucleotide substitution at position 156 (A in MG1363, T in KW2). The *rpsL* allele of KW2 is disclosed as SEQ ID NO:25 (Figure 4A). To ensure efficient recombination, the transforming PCR product also contains upstream and downstream recombination arms of ~1.85 kb surrounding the *strA1* mutation. Transformation assays were performed with the eight previously selected clones of the $ComX^+$ reporter strain (BLD101 [pGhP32comX_{MG}]) and the control strain (BLD101 [pG^+host9], empty vector) using the standard protocol reported in Material and Methods. Validation of natural transformation is made by sequencing the *rpsL* region covering the point mutations from the donor DNA conferring streptomycin resistance using primers RpsL Univ UP and RpsL Univ DN.

Remarkably, the $ComX^+$ clones 02 and 04 that displayed the highest P_{comGA} activation (≥ 7 × 10^5 RLU OD_{600}^{-1}) yielded mutation frequencies ~15-fold higher than the background level of spontaneous mutation that was calculated in the absence of DNA (Figure 4B). After

subtraction of the background, a transformation rate of up to 4 × 10^{-5} transformants per µg of DNA (~10^4 transformants ml^{-1}) was obtained for clone 02 which displays the highest P_{comGA} activation. In contrast, the negative control strain had a spontaneous mutation rate of ~1 x 10^{-7} transformants per µg of DNA.

The *rpsL* ORF of 10 Str^r–derivatives of cl02 was amplified by PCR and sequenced. In all cases, we observed the co-transfer of *strA1* (mutation A→T at position 167 of the *rpsL* gene) and the closely-located T→A mutation at position 156. In some cases, the T→G mutation at position 39 was also co-transferred with *strA1*. The chimeric nature of *rpsL* in some Str^r $ComX^+$ derivatives of KW2 (*i.e.* presence of both mutations at positions 156 and 167 without the mutation at position 39) ultimately demonstrates that a recombination process occurred between the exogenous and chromosomal DNA (Figure 4A). In contrast, this rearrangement was not observed in the *rpsL* gene of spontaneous Str^r mutants obtained in the negative control experiments (*i.e.* assays performed in absence of exogenous DNA, or with the control strain carrying the empty vector in presence of exogenous DNA). These results show that exogenous DNA can enter KW2 cells and be integrated in their chromosome by homologous recombination when a certain threshold of *comX* expression is reached.

b) Construction of deletion mutants by natural competence in L. lactis subsp. cremoris KW2 overexpressing comX

The previous result (Example 4, section a) strongly suggests that DNA transfer occurs in *L. lactis* KW2. The 3 mutations transferred by natural transformation are grouped on a 128-bp fragment. If a longer DNA fragment could be similarly integrated in the *L. lactis* chromosome remains to be determined.

We wondered if overlap PCR as donor DNA could equivalently allow gene insertions or gene deletions. The idea was to replace the target gene by an antibiotic resistance cassette, i.e. the chloramphenicol resistance cassette P_{32}-*cat*. For this purpose, a DNA fragment was constructed by overlap PCR containing the P_{32}-*cat* cassette flanked by two homologous arms (minimum ~ 1.5kb) containing the upstream and downstream regions of the targeted gene.

To this end, exogenous DNA polynucleotides containing P_{32}-*cat* surrounded by KW2-specific recombination arms (~ 1.5 kb) were assembled *in vitro* by overlapping PCR to target the *comEC, mecA, ciaRH, covRS* or *clpC* gene (see Materials and Methods for details) and transferred by natural transformation in the $ComX^+$ strain (cl02). Validation of natural transformation is made by sequencing the targeted region (*comEC, mecA, ciaRH, covRS* or *clpC*, which should contain the chloramphenicol resistance cassette P_{32}-*cat*) using primers listed in Table 3.

The transformation rate observed for overlap PCR products was ~ 1.2 x 10^{-6} to 1.1 x 10^{-4} transformants per µg of DNA for the different overlap DNA fragments that were tested (see Figure 5). Compared to the transformation rate observed for the exchange of a homologous DNA fragment containing only three point mutations (*rpsL** donor DNA; 8 x 10^{-4} transformants per µg of DNA), these rates are relatively high for DNA double recombination deletion/replacement.

Example 5: A KW2 Δ*comEC* mutant is unable of natural competence transformation

To confirm that the observed horizontal DNA transfer in ComX$^+$ KW2 cells was indeed mediated by natural competence, and not by phage transduction or conjugation, we investigated the role of the ComEC protein, which is essential for the uptake of transforming DNA through the cell membrane (the *comEA* gene, together with the *comFA*, *comGA*, *dprA*, *coiA*, *ssbA*, *radA*, *radC*, *recA* and *recX* genes are preceded by a Com-box and have been found to be activated in KW2 following constitutive *comX* expression; data not shown).

To create the Δ*comEC* strain, clone 02 of the ComX$^+$ reporter strain, which was tested above, was grown in CDM conditions in presence of PCR products encompassing the *comEC* gene disrupted by the insertion of the chloramphenicol resistance cassette P_{32}-*cat* (see Materials and Methods). Four mutants with disrupted *comEC* (BLD102 [pGhP32comX_{MG}] cl01 to cl04) were validated by PCR for P_{32}-*cat* insertion in *comEC*. Transformation assays with the mutated *rpsL* allele showed that the frequencies of appearance for Str^r clones in all tested Δ*comEC* derivatives were similar to the background level of spontaneous *rpsL* mutation frequencies (< 10^{-7}) (Figure 6). Although heterogeneity in P_{comGA} activation was observed between clones as previously reported for the WT ComX$^+$ reporter strain, half of the Δ*comEC* derivative clones (i.e. cl01 and cl03) displayed maximum specific Lux activity similar to the transformable WT strains (> 1.0 × 10^6 RLU OD_{600}^{-1}) (Figure 4B). This shows that the transformation defect in these Δ*comEC* clones does not result from a too low production of ComX.

Taken together, these results demonstrate that natural DNA transformation could be activated by ComX overexpression in *L. lactis* subsp. *lactis* KW2. Moreover, to the best of our knowledge, these data provide the first ever experimental evidence of transformation of *L. lactis* by natural competence.

Example 6: Natural competence in two strains of the *L. raffinolactis* species

Following the positive results obtained regarding natural competence in *Lactococcus lactis* strains, other strains of the *Lactococcus* genus were tested. Two strains of *L. raffinolactis* were

able to capture plasmid pGhost-Core (15 µg / 300 µl) used as donor DNA: LMG13098 and LMG14164. These results suggest that these two strains of *L. raffinolactis* are naturally competent for plasmid transformation and that, in these strains, natural competence is independent of artificial *comX*-overexpression.

The fact that another *Lactococcus* species could be transformed by competence opens additional possibilities for industrial applications.

Example 7: Transformation by natural competence in 2 *Lactococcus lactis* subsp. *lactis* strains

Two *Lactococcus lactis* subsp. *lactis* strains, SL12651 and SL12653, carrying all the essential late *com* genes (Figure 1) were tested. As donor DNA, PCR fragments which encompass the mutated *rpsL* allele (*rpsL**) of a spontaneous streptomycin-resistant (Str^r) clone of *L. lactis* subsp. *lactis* IL1403 was used. Cells were pre-cultured overnight in a complex medium supplemented with glucose (e.g. M17G) at 30°C. Cells were washed twice with distilled water and inoculated at an OD_{600} of 0.05 in 200 µl M17G containing 25 µg mL^{-1} donor DNA *rpsL**. After 24 hours of culture at 30°C, cells incubated or not with donor DNA were spread onto agar plates comprising the complex medium supplemented with glucose (e.g. M17G) and appropriate antibiotic (i.e. streptomycin). CFUs were counted after 48 hours of incubation at 30°C. Remarkably, SL12651 and SL12653 yielded a transformation rate of up to 1 x 10^{-6} of DNA when grown in M17G rich medium (Figure 7A; +DNA). In contrast, the negative control in absence of donor DNA had a spontaneous mutation rate of 6 x 10^{-9} (Figure 7A; -DNA). The transformants were validated by sequencing the *rpsL* region covering the point mutation from the donor DNA conferring streptomycin resistance.

Then, the SL12653 strain was assayed in the same conditions with variable quantity of donor DNA (0.5, 2.5, 5 and 25 µg mL^{-1}). It has been shown that the transformation rate obtained is directly correlated to the initial quantity of donor DNA, yielding up to a transformation rate of 5 x 10^{-6} (Figure 7B).

Moreover, to confirm that the observed horizontal DNA transfer was mediated by natural competence, the *comX* gene of SL12653 was knocked-out (as described in example 5 above). Three mutants of SL12653 with disrupted *comX* gene were designed by inserting PCR products encompassing the *comX* gene disrupted by the insertion of the chloramphenicol resistance cassette P_{32}-*cat* and validated by PCR for P_{32}-*cat* insertion. Transformation assays with *rpsL** as donor DNA in all Δ*comX* clones ($ComX^-$) showed that the frequencies of appearance of Str^r clones were similar to the background level of spontaneous mutation

frequencies (Figure 7C). These results confirm that in SL12653, the transformation is dependent on the expression of the endogenous *comX* gene.

Finally, the transformability of the SL12653 strain was also assayed by overexpressing the *comX* gene. Thus, an inducible *comX* expression plasmid [pGhPxylTcomX$_{IO}$] was constructed by cloning the *comX* gene from strain *L. lactis* subsp. *lactis* IO-1 under the control of the P_{xylT} promoter from strain IO-1 on the thermosensitive plasmid pG$^+$host9. This plasmid is a variant of pGhPxylTcomX$_{MG}$ (pGIFPT001) described in David *et al.*, 2017. The transformation procedure described in David *et al* (2017) was followed. In presence of xylose (1%), SL12653 [pGhPxylTcomX$_{IO}$] yielded a transformation rate at least 20-fold higher than in absence of xylose, confirming that the overexpression of *comX* in SL12653 increased its transformability by natural competence.

Materials and Methods

- *Bacterial strains, plasmids, and growth conditions*

The bacterial strains and plasmids used in this application are listed in Table 2.

Strain or plasmid	Characteristics [a]	Source or reference
E. coli		
TG1	*supE hsd*Δ*5 thi* Δ(*lac-proAB*) F′[*traD36 proAB*$^+$ *lacI*^{q} *lacZ*Δ*M15*]	Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y.
EC1000	Km^r, recA$^+$; MC1000 containing a copy of the *repA* gene from pWV01 in its chromosome	Law, J., G. Buist, A. Haandrikman, J. Kok, G. Venema, and K. Leenhouts. 1995. J. Bacteriol. 177:7011-7018.
L. lactis		
MG1363	Laboratory strain, dairy origin	Gasson, M. J. 1983. J. Bacteriol. 154:1-9.
KW2	Wild-type isolate from corn fermentation	Kelly, W. J., E. Altermann, S. C. Lambie, and S. C. Leahy. 2013. Front Microbiol. 4:257.
IL1403	Laboratory strain, dairy origin	Chopin, A., M. C. Chopin, A. Moillo-Batt, and P. Langella. 1984. Plasmid 11:260-263
IO-1	Wild-type isolate from water in the drain pit of a kitchen sink	Ishizaki A, Osajima K, Nakamura K, Katsunori K, Hara T, and Ezaki T. 1990. J. Gen. Appl. Microbiol., 36, 1–6
SL12651	Wild-type isolate from plant material (maize)	DuPont/Danisco collection
SL12653		
BLD101	KW2 *kw2_0563*::$P_{comGA[MG]}$-*luxAB*	This application
BLD102	BLD101 *comEC*::P_{32}-*cat*	This application
BLD107	BLD101 *mecA*::P_{32}-*cat*	This application
BLD108	BLD101 *ciaRH*::P_{32}-*cat*	This application
BLD109	BLD101 *covRS*::P_{32}-*cat*	This application
BLD105	BLD101 *clpC*::P_{32}-*cat*	This application
L. raffinolactis		
LMG13098	Wild-type isolate from garden carrots	LMG collection
LMG14164	Wild-type isolate from goose	LMG collection

Plasmids		
pGEM®-T easy	Ap^r ; cloning vector	Promega
pG^+host9	Em^r Ts	Maguin, E., H. Prevost, S. D. Ehrlich, and A. Gruss. 1996. J. Bacteriol. 178:931-935
pGhost-Core	Em^r Ts; pG^+host9 derivative containing the Core part of the resolution site IRS recognized by the TnpI from Tn*4430*	This application
pMG36eT	Em^r; *E. coli-L. lactis* shuttle vector containing the P_{32} constitutive promoter from *L. lactis*	Fontaine, L. and P. Hols. 2008.Appl. Environ. Microbiol. 74:1102-1110.
pJIM4900	Em^r Ts; pG^+host9 derivative containing the *luxAB* genes of *Photorhabdus luminescens*	E. Guédon, (laboratory collection)
pXL	Em^r; pTRKH2 derivative containing the *luc* reporter gene	Blomqvist T, Steinmoen H, Håvarstein LS. Appl Environ Microbiol. 2006. Oct;72(10):6751-6.
pSEUDOPusp45GFP	Em^r; suicide vector containing the *llmg_pseudo_10*(*kw2_0563*)::P_{usp45}-*gfp*$^+$ insertion cassette	Overkamp, W., K. Beilharz, W. R. Detert Oude, A. Solopova, H. Karsens, A. Kovacs, J. Kok, O. P. Kuipers, and J. W. Veening. 2013. Appl. Environ. Microbiol. 79:6481-6490.
pUC18Cm	Ap^r Cm^r; pUC18 derivative containing the P32-*cat* cassette	Goffin, P., F. Lorquet, M. Kleerebezem, and P. Hols. 2004. J. Bacteriol. 186:6661-6666.
pUC18Ery	Ap^r Em^r; pUC18 derivative containing an erythromycin resistance marker	van Kranenburg, R., J. D. Marugg, I. I. van Swam, N. J. Willem, and W. M. de Vos. 1997. Mol. Microbiol. 24:387-397.
pNZ5319	Em^r Cm^r; pACYC184 derivative containing the P32-*cat* cassette surrounded by *lox* sites	Lambert, J. M., R. S. Bongers, and M. Kleerebezem. 2007. Appl. Environ. Microbiol. 73:1126-1135.
pGhPcomGAluxAB	Em^r Ts; pG^+host9 derivative containing the *llmg_pseudo_10* (*kw2_0563*)::$P_{comGA[MG]}$-*luxAB* insertion cassette	This application
pGhP32comX$_{MG}$	Em^r Ts, pG^+host9 derivative carrying *comX* of strain MG1363 under the control of the constitutive promoter P_{32}	This application
pGhP32comX$_{IO}$	Em^r Ts, pG^+host9 derivative carrying *comX* of strain IO-1 under the control of the constitutive promoter P_{32}	This application
pGhP32comX$_{MG}$-$P_{comGA[MG]}$-*luc*	pGhP32comX$_{MG}$ derivative carrying a $P_{comGA[MG]}$-*luc* fusion	This application
pGhP32comX$_{IO}$-$P_{comGA[IO]}$-*luc*	pGhP32comX$_{IO}$ derivative carrying a $P_{comGA[IO]}$-*luc* fusion	This application
pGEMrpsL*	Ap^r, pGEM®-T easy derivative carrying the *rpsL** gene (*strA1* allele)	This application
pUCcomECcat	Ap^r Em^r Cm^r, pUC18Ery derivative allowing the insertion of P_{32}-*cat* at the *comEC* locus	This application
pGhPxylTcomX$_{IO}$	Em^r Ts, pG^+host9 derivative carrying *comX* of strain IO-1 under the control of the inducible promoter P_{xylT} from IO-1	This application

Table 2: list of used bacterial strains and plasmids

[a] Em^r, Ap^r, Cm^r and Ts: erythromycin, ampicillin, chloramphenicol resistance and thermo-sensitive RepA protein, respectively.

Escherichia coli was grown with shaking at 37°C in Lysogeny-Broth (LB) broth. Plasmids derived from pMG36e and pG$^+$host9 were constructed in *E. coli* strains TG1 and EC1000, respectively. *L. lactis* and *L. raffinolactis* were cultivated in M17 (Becton, Dickinson, and Company), Todd Hewitt broth (THB) (Becton, Dickinson, and Company) or CDM at 30°C without agitation. M17 and THB were supplemented with 0.5% (w/v) of glucose (M17G and THBG, respectively). Solid agar plates were prepared by adding 2% (w/v) agar to the medium. When required, 5 µg ml^{-1} of erythromycin, 1 mg ml^{-1} of streptomycin, and/or 10 µg ml^{-1} of chloramphenicol were added to the medium for *L. lactis* and *L. raffinolactis*; and 250 µg ml^{-1} of erythromycin, 250 µg ml^{-1} of ampicillin, 10 µg ml^{-1} of chloramphenicol for *E. coli*.

- *Detection of absorbance and luminescence.*

Growth (OD_{600}) and luciferase (Lux) activity were monitored at 10-minutes intervals in a Varioskan Flash multi-mode reader (ThermoFisher). The luciferase activity is expressed in relative light units (RLU) and the specific luciferase activity in RLU OD_{600}^{-1}.

- *DNA techniques and electrotransformation*

General molecular biology techniques were performed according to the instructions given by Sambrook et al. (1989). Electrotransformation of *E. coli* and *L. lactis* was performed as previously described. The electrotransformed cells of *L. lactis* were immediately resuspended in 1 ml of M17G and incubated for 6 hours at 30 °C. Chromosomal DNAs of *L. lactis* were prepared as previously described. PCRs were performed with Phusion DNA polymerase (NEB) in a GeneAmp PCR system 2400 (Applied Biosystems). The primers used in this application are listed in Table 3.

Primer name	Sequence (5'-3')
Primers used for the construction of the constitutive *comX* expression plasmid pGhP32comX$_{MG/IO}$:	
BID_ComXSDLLCup	AAAAGAGCTCAATTATGAAAAAGAGG
BID_ComXSDLLCdown	AAAACTGC AGTTAATCATCATCTCG
BID_ComXSDLLLup	AAAAGAGCTCATAAAAGGAGAACTTTCC
BID_ComXSDLLLdown	AAAACTGCAGTCACTCTTCGTCTTC
BID_pMGP32UpMfeI	ATATCAATTGGTCCTCGGGATATGATAAG
BID_pMGTerDown	GACTTTGAACCTCAACTCC
Primers used for the construction of the P$_{comGA[MG]}$-*luxAB* reporter strain BLD101:	
BID_LuxLLCf1	ATAGTCTCGAGTTTAAGCAATTGAATCGCTAG
BID_LuxLLCr1	GCAAAAAGTTTCCAAATTTCATACTAGAATATACGCAATTTG
BID_LuxLLCf2	CAAATTGCGTATATTCTAGTATGAAATTTGGAAACTTTTTGC
BID_LuxLLCr2	GCGAAAGGATCCCTATTAGGTATATTCCATGTGG
BID_P3pseudoLLC	GCTCCCTCGAGGGCGGCTCTGTTGGATTAATATATGG

Primers used for the construction of portable *luc* reporter vectors:	
BID_LucLLCr1	CTTTATGTTTTTGGCGGATCTCATACTAGAATATACGCAATTTG
BID_LucLLCf2	CAAATTGCGTATATTCTAGTATGAGATCCGCCAAAAACATAAAG
BID_LucLLCr2	GCGAAAGGATCCTTACAATTTGGGCTTTCCG
BID_PcomGALLCF1*	AAAACCCGGGTTTAAGCAATTGAATCGCTAG
BID_PcomGALLLF1*	5' AAAACCCGGGAAATAAATGGCTACAAAATT
BID_lucR1*	AAAACGGCCGTTACAATTTGGGCTTTCCG
BID_luxLLLf1	ATAGTCTCGAGAAATAAATGGCTACAAAATT
BID_lucLLLr1	CTTTATGTTTTTGGCGGATCTCATACTAGACTATACGCAAATAATC
BID_lucLLLf2	GATTATTTGCGTATAGTCTAGTATGAGATCCGCCAAAAACATAAAG
BID_lucLLLr2	GCGAAAGGATCCTTACAATTTGGGCTTTCCG
Primers used for the construction of pGhost-Core	
DD-pGhost-CoreUp	AGCTTCCTAATACAACACAATTAATATTGTGTTGTATTATTG
DD-pGhost-CoreDW	AATTCAATAATACAACACAATATTAATTGTGTTGTATTAGGA
Primers used for *rpsL* sequencing:	
RpsL Univ UP	ATGCCTACAATTAACCAAT
RpsL Univ DN	CACCGTATTTAGAACGG
LR_RpsL Univ UP	ATGCCTACTATTAACCAAT
LR_RpsL Univ DN	TACCGTATTTAGAACGG
Primers used for *rpsL* amplification:	
BID_LLcdacARpsL	AGTAGTATCAGCACTGACAGC
BID_LLlcfusARpsL	ACACCTTTGTTCTTGAAGG
primers used for the construction of the *comEC* disruption mutant:	
BID_ComECLLCUp	AAAGAGCTCAAAATAAAAATGAAATTATGG
BID_ComECLLCDown	AAAGCTAGCGGGAAAAAATTGTGAATTAC
BID_CatUpSpeI	AAAAACTAGTGCAGTTTAAATTCGGTCCTCGG
BID_CatDownSpeI	AAAAACTAGTGTACAGTCGGCATTATCTCAT
Primers used for the construction and validation of the *mecA* deletion mutant:	
BID_fgt01FmecArec	CTTTAATGATGGAATGATTG
BID_fgt01RVmecArec	CTATTAATCTTATCATATCCCGAGGATCCATATAACTATATGAAACC
BID_fgt02Fcat	TCCTCGGGATATGATAAGATTAATAG
BID_fgt02RVcat	TCTCATATTATAAAAGCCAGTCATTAG
BID_fgt03FmecArec	CTAATGACTGGCTTTTATAATATGAGACTTAGAAAAATCTAAATATGGTTG
BID_fgt03RVmecArec	GAAGATTTTTAATTTCAAGTGTAG
BID_mecAKOF	TCAGTACCGAAAAACGAATG
BID_mecAKORV	ATTTACCAGTTCCGTTAGG
Primers used for the construction and validation of the *ciaRH* deletion mutant:	
BID_ciaRHUPF	TAACAATGATACAGAAGATG
BID_ciaRHUPRVRec	CTATTAATCTTATCATATCCCGAGGATATTTTTGTCTTGTACTAGG
BID_fgt02Fcat	TCCTCGGGATATGATAAGATTAATAG

BID_fgt02RVcat	TCTCATATTATAAAAGCCAGTCATTAG
BID_ciaRHDownFRec	CTAATGACTGGCTTTTATAATATGAGAGAGAGAAAAAAATTACTGAC
BID_ciaRHDownRV	AAAATCTGTTAGAACTGTTG
BID_ciaRHKODiagF	AAGATAAGGCAGTTGAAATG
BID_ciaRHKODiagRv	TCACCATGTGAATAAAGTCC
Primers used for the construction and validation of the *covRS*deletion mutant:	
BID_covRSfgt01F	CAAAAATGTGAAGCTTATC
BID_covRSfgt01RVRec	CTATTAATCTTATCATATCCCGAGGATGCATAATTCGATTTC
BID_fgt02Fcat	TCCTCGGGATATGATAAGATTAATAG
BID_fgt02RVcat	TCTCATATTATAAAAGCCAGTCATTAG
BID_covRSfgt03FRec	TAATGACTGGCTTTTATAATATGAGACTATTTATCTGCTCATTTC
BID_covRSfgt03RV	GAGCTTTTTTCAAATCTTC
BID_covRSKOFdiag	GAAGTGATGAATGAGATG
BID_covRSKORVdiag	CTTTCTCATCAATTGAGAC
Primers used for the construction and validation of the *clpC* deletion mutant:	
BID_clpCUPF	CTTTGGGTTCTAATTTATC
BID_clpCUPRVRec	CTATTAATCTTATCATATCCCGAGGACGTTGGTGTATATTTTAC
BID_fgt02Fcat	TCCTCGGGATATGATAAGATTAATAG
BID_fgt02RVcat	TCTCATATTATAAAAGCCAGTCATTAG
BID_clpCDownFRec	CTAATGACTGGCTTTTATAATATGAGATAGAAATAAAGGAAAGGAC
BID_clpCDownRV	TTGCTTTAAGGATAGTTTC
BID_clpCFdiag	AGAAGCCAATAATGACGATG
BID_clpCRVdiag	AGAATTCTGATGATGCACAGTC
Primers used for the construction of the inducible comX expression plasmid pGhPxylTcomX$_{IO}$:	
FT_pGhPxylcomXIOsacIIrv	AGCGCCGCGGTGGGATCCTCTAGAGTC
FT_pGhPxylcomX	CTGCAGGCATGCACATCATCAACTTGAAGGG
FT_PxylTIOsacIIfw	CCCACCGCGGTGGAGATACGAACAAATTAG
FT_PxylTIOrv	GATAGTAACTCCTTAATTTTTATTTGC
FT_comXIOrecfw	GCAAATAAAAATTAAGGAGTTACTATCATGACATATTACTTGGAAGAAGAGGATTTTG
FT_comXIOrecrv	CCTTCAAGTTGATGATGTGCATGCCTGCAGTCACTCTTCGTCTTC
Primers used for the construction and validation of the SL12653-*comX* deletion mutant	
FT_comXlocusfw	TGACCATGTTACACAAGCCTATATCCT
FT_comXrecrv	CGCCCTTATGGGATTTATCTTCCTTACTTCGTTTCTTTGCATAACTTCGTCTTAAT
Uplox66	TAAGGAAGATAAATCCCATAAGG
Dnlox71	TTCACGTTACTAAAGGGAATGTA
FT_comXrecfw	TCTACATTCCCTTTAGTAACGTGAACCATGACCATTTTATAGGTTTAGATGTTTATG
AR_comxDNspecR	CGGTGTTCCTCCATATATCTACGC
FT_PxylcomXfw	CGCTAAACTCAACAGGTGATCCGATTG

Table 3: list of primers

- *Construction of plasmid pGhP32comX$_{MG}$*

As a representative of the *cremoris* subspecies, the *comX* gene from the laboratory strain MG1363 was initially chosen. ComX proteins of this subspecies are highly conserved with at least 98% of identity. The *comX* gene was amplified by PCR using primers BID_ComXSDLLCup/BID_ComXSDLLCdown and inserted into plasmid pMG36eT under the control of the constitutive P_{32} promoter by SacI/PstI cloning, yielding plasmid pMGP32comX$_{MG}$. The P_{32}-*comX$_{MG}$* fusion from pMGP32comX$_{MG}$ was amplified by PCR with primers BID_pMGP32UpMfeI/BID_pMGTerDown, digested by MfeI/KpnI, and cloned in the EcoRI/KpnI-digested thermosensitive pG$^+$host9 vector. The resulting plasmid was named pGhP32comX$_{MG}$.

- *Construction of plasmid pGhP32comX$_{IO}$*

As a representative of the *lactis* subspecies, the *comX* gene from the IO-1 strain was chosen. The *comX* gene was amplified by PCR using primers BID_ComXSDLLLup/BID_ComXSDLLLdown and inserted into plasmid pMG36eT under the control of the constitutive P_{32} promoter by SacI/PstI cloning, yielding plasmid pMGP32comX$_{IO}$. The P_{32}-*comX$_{IO}$* fusion from pMGP32comX$_{IO}$ was amplified by PCR with primers BID_pMGP32UpMfeI/BID_pMGTerDown, digested by MfeI/KpnI, and cloned in the EcoRI/KpnI-digested thermosensitive pG$^+$host9 vector. The resulting plasmid was named pGhP32comX$_{IO}$.

- *Construction of plasmid pGhost-Core*

The Core part of the resolution site (IRS) recognized by the TnpI recombinase from Tn*4430* was assembled by using the complementary primers DD-pGhost-CoreUp/DD-pGhost-CoreDW. The resulting DNA fragment was cloned between HindIII and EcoRI sites in plasmid pG$^+$host9. The resulting plasmid, named pGhost-Core, was transformed in *E. coli* harbouring plasmid pGIV004 (TnpI$^+$) for obtaining multimeric forms (Vanhooff V, Galloy C, Agaisse H, Lereclus D, Révet B, Hallet B. Mol Microbiol. 2006 May;60(3):617-29).

- *Construction of P$_{comGA[MG]}$-luxAB reporter strain BLD101*

The P$_{comGA[MG]}$ promoter was amplified by PCR from chromosomal DNA of *L. lactis* MG1363 (identical nucleotide sequence between MG1363 and KW2) with primers BID_LuxLLCf1/BID_LuxLLCr1 (PCR1 product). The *luxAB* genes were amplified by PCR from plasmid pJIM4900 with primers BID_LuxLLCf2/BID_LuxLLCr2 (PCR2 product). The P$_{comGA[MG]}$-*luxAB* fusion was created by overlapping PCR using PCR1 and PCR2 products and primers BID_LuxLLCf1/BID_LuxLLCr2. The resulting fusion was cloned in plasmid pSEUDOPusp45GFP using restriction enzymes XhoI and BamHI, yielding plasmid

pSEUDOPusp45PcomGAluxAB. In order to remove the P_{usp45} promoter, the entire vector except the P_{usp45} promoter was amplified by inverse PCR with primers BID_P3pseudoLLC/BID_LuxLLCf1 and self-ligated after XhoI digestion, leading to plasmid pSEUDOPcomGAluxAB. The insertion cassette *llmg_pseudo_10*::$P_{comGA[MG]}$-*luxAB* was excised from plasmid pSEUDOPcomGAluxAB and cloned into the pG^+host9 thermosensitive vector using restriction enzymes KpnI/EagI. The resulting plasmid pGhPcomGAluxAB was then electro-transformed in strain KW2 and used to integrate the $P_{comGA[MG]}$-*luxAB* cassette at locus *kw2_0563* (*llmg_pseudo_10* in MG1363) by double homologous recombination, resulting in the reporter strain KW2 *kw2_0563*::$P_{comGA[MG]}$-*luxAB* (strain BLD101).

- *Construction of portable luc reporter systems*

The $P_{comGA[MG]}$ promoter was amplified by PCR from chromosomal DNA of *L. lactis* MG1363 with primers BID_LuxLLCf1/BID_LucLLCr1 (PCR1 product). The *luc* gene was amplified by PCR from plasmid pXL with primers BID_LucLLCf2/BID_LucLLCr2 (PCR2 product). The $P_{comGA[MG]}$-*luc* fusion was created by overlapping PCR using PCR1 and PCR2 products and primers BID_LuxLLCf1/BID_LucLLCr2. The resulting fusion was cloned in plasmid pSEUDOPusp45GFP using restriction enzymes XhoI and BamHI, yielding plasmid pSEUDOPusp45PcomGAluc. In order to remove the P_{usp45} promoter, the entire vector except the P_{usp45} promoter was amplified by inverse PCR with primers BID_P3pseudoLLC/BID_LuxLLCf1 and self-ligated after XhoI digestion, leading to plasmid pSEUDOPcomGAluc. The reporter cassette $P_{comGA[MG]}$-*luc* was amplified by PCR from pSEUDOPcomGAluc (primers BID_PcomGALLCF1*/ BID_lucR1*) and cloned between XmaI and EagI into the pGhP32comX_{MG} plasmid. The resulting reporter plasmid was named pGhP32comX_{MG}-$P_{comGA[MG]}$-*luc*.

The $P_{comGA[IO]}$ promoter was amplified from the IO-1 chromosome (primers BID_luxLLLf1/ BID_lucLLLr1) and the luciferase gene (*luc*) was amplified from plasmid pXL (primers BID_lucLLLf2/BID_lucLLLr2). The cassette $P_{comGA[IO]}$-*luc* was created by overlapping PCR with primers BID_luxLLLf1/BID_lucLLLr2.The cassette $P_{comGA[IO]}$-*luc* was then amplified from the overlapping PCR product with primers BID_PcomGALLLF1*/ BID_lucR1* for XmaI/EagI cloning into pGhP32comX_{IO}. The resulting reporter plasmid was named pGhP32comX_{IO}-$P_{comGA[IO]}$-*luc*.

- *Isolation of a rpsL mutant conferring resistance to streptomycin*

Spontaneous streptomycin-resistant MG1363 clones were isolated on 1 mg ml^{-1} streptomycin-containing plates. After the sequencing of the *rpsL* gene with primers RpsL Univ UP/RpsL Univ DN, one spontaneous mutant resulting in a mutation (K56I) into the ribosomal protein S12 that

was previously shown to confer resistance to streptomycin was selected (Figure 6). A 3.7-kb fragment containing the *rpsL* mutated gene (*strA1* allele) was amplified by PCR with primers BID_LLcdacARpsL/BID_LLlcfusARpsL and cloned into the pGEM®-T easy vector (Promega), yielding plasmid pGEMrpsL*. This plasmid was used as template to generate the 3.7-kb PCR product with primers BID_LLcdacARpsL/BID_LLlcfusARpsL that was used as donor DNA in natural transformation assays of strain KW2.

- *Standard natural transformation assay*

The BLD101 reporter strain carrying the pGhP32comX_{MG} plasmid (BLD101 [pGhP32comX_{MG}]) was grown overnight in M17G at 30°C. Then, 1.5 ml of the pre-culture was diluted in 8.5 ml of fresh M17G medium to restart the culture. After 2 hours of growth, cells were washed twice in distilled water and OD_{600} was adjusted to 0.05 in CDM containing erythromycin (5 µg ml^{-1}) and supplemented with either 5% (v/v) glycerol or 5% (w/v) mannitol used as potential osmo-stabilizers. Typically, 5 µg of DNA was added in 300 µl of inoculated medium and the culture was further incubated during 6 hours at 30°C. Cells were then spread on M17G agar plates supplemented with appropriate antibiotics and CFUs were counted after 48 hours of incubation. The transformation frequency was calculated as the number of antibiotic-resistant CFU ml^{-1} divided by the total number of viable CFU ml^{-1}. In the case of streptomycin-resistant transformants, antibiotic-resistant CFU ml^{-1} corresponds to the number of transformants obtained in presence of DNA less the number of spontaneous transformants obtained in conditions where no DNA is added in the culture. The transfer of the mutation conferring streptomycin resistance was confirmed by DNA sequencing of the *rpsL* gene after its amplification by PCR using primers RpsL Univ UP/RpsL Univ DN.

- *Disruption of comEC by natural transformation*

A *comEC*-containing DNA fragment of ~3.2 kb was amplified by PCR with primers BID_ComECLLCUp/BID_ComECLLCDown. Then, the PCR product was digested by SacI/NheI and cloned into the SacI/XbaI-digested suicide plasmid pUC18Ery (van Kranenburg et al., 1997), yielding plasmid pUCcomEC. To generate a *comEC* disruption cassette that allows the selection of double crossing-over recombinants, the P_{32}-*cat* fusion conferring resistance to chloramphenicol was cloned in the middle of the *comEC* gene. For this purpose, the P_{32}-*cat* cassette was amplified by PCR from plasmid pNZ5319 (Lambert et al., 2007, Appl. Environ. Microbiol. 73:1126-1135) with primers BID_CatUpSpeI/BID_CatDownSpeI. The amplification product was digested by SpeI and cloned into the XbaI-digested pUCcomEC, yielding plasmid pUCcomECcat. This suicide plasmid was used to generate high quantity of donor DNA by PCR amplification for *comEC* disruption by natural transformation. The insertion

of the P_{32}-*cat* cassette in the *comEC* gene of KW2 transformants was validated by PCR (primers in Table 3).

- *Deletion of mecA, ciaRH, covRS, and clpC* genes *by natural transformation*

The *mecA, ciaRH, covRS, and clpC* genes were similarly inactivated by the exchange of their ORFs by the P_{32}-*cat* cassette using double crossing-over events. For this purpose, overlapping PCR products containing the P_{32}-*cat* cassette flanked by two recombination arms of ~1.5 kb (upstream and downstream homologous regions) were generated as previously reported. Briefly, upstream, downstream, and P_{32}-*cat* fragments were separately amplified by PCR, purified, mixed in equimolar concentration, and assembled by overlapping PCR by using the most external primers (see list of primers in Table 3). 5 µg of the obtained overlapping PCR product was used as donor DNA for natural transformation of strain BLD101 [pGhP32comX_{MG}]. The correct insertion of the P_{32}-*cat* cassette in each targeted locus of the KW2 transformants was validated by PCR (see list of primers in Table 3). To obtain the final mutant strains, the thermosensitive vector pGhP32comX_{MG} was cured by growing the strains overnight at 37°C without erythromycin. The cultures were subsequently diluted and plated on M17G agar without erythromycin at 30°C. The resulting colonies were streaked in parallel on M17G plates with and without erythromycin. Absence of plasmid pGhP32comX_{MG} in Ery^S clones was validated by PCR.

- *Induction of natural competence in Lactococcus raffinolactis*

Wild-type *Lactococcus raffinolactis (i.e., L. raffinolactis* strains which have not been previously engineered for the overproduction of the *comX* gene) were grown overnight in M17G at 30°C. 1.5 ml of the pre-culture was diluted in 8.5 ml of fresh M17G medium to restart the culture. After 2 hours of growth, cells were washed twice in distilled water and OD_{600} was adjusted to 0.05 in CDM supplemented with either 5% (v/v) glycerol or 5% (w/v) mannitol used as potential osmo-stabilizers. 15 µg of plasmid pGhost-Core was added in 300 µl of inoculated medium and the culture was further incubated during 6 hours at 30°C. Cells were then spread on M17G agar plates supplemented with appropriate antibiotics and CFUs were counted after 48 hours of incubation. The transformation frequency was calculated as the number of antibiotic-resistant CFU ml^{-1} divided by the total number of viable CFU ml^{-1}.

- *Natural competence in Lactococcus lactis subsp lactis SL12651 and SL12653 strains*

The *L. lactis* subsp. *lactis* SL12653 and 12651 strains were grown overnight at 30°C. Cells were washed twice in distilled water and OD_{600} was adjusted to 0.05 in M17G. Typically, 5 µg of donor DNA was added in 200 µl of inoculated medium (25 µg/ml) and the culture was further incubated during 24 hours at 30°C. Cells were then spread on M17G agar plates supplemented

with appropriate antibiotics and CFUs were counted after 48 hours of incubation at 30°C. The transformation frequency calculated exactly as described above (see Standard natural transformation assay).

The same experiments were done in SL12653 with various concentrations of donor DNA (0.5, 2.5, 5 and 25 µg/ml)

- *Construction of plasmid pGhPxylTcomXIO*

As a representative of the *lactis* subspecies, the *comX* gene and the promoter of the *xylT* gene from the IO-1 strain were chosen. The *comX* gene was amplified by PCR using primers FT_comXIOrecfw and FT_comXIOrecrv (PCR1), both containing overlapping sequences. The *xylT* promoter region was amplified by PCR using primers FT_PxylTIOsacIIfw and FT_PxylTIOrv (PCR2). The carrying vector was amplified from plasmid pGhP32comX_{MG} and amplified by PCR using primers FT_pGhPxylcomXIOsacIIrv and FT_pGhPxylcomX (PCR3). The three PCR products were purified, mixed in an equimolar concentration and assembled by overlapping PCR using the most external primers, containing a SacII restriction site. The amplification product was digested by SacII and self-ligated. The resulting plasmid was named pGhPxylTcomX$_{IO}$.

- *Transformation assay in SL12653 mutants deleted for the comX gene*

The *comX* gene of SL12653 was inactivated by exchange of their ORF by the P_{32}-*cat* cassette using double crossing-over events. For this purpose, overlapping PCR products containing the P_{32}-*cat* cassette flanked by two recombination arms of ~1.5 kb (upstream and downstream homologous regions) were generated as previously reported. Briefly, upstream, downstream, and the P_{32}-*cat* fragments were separately amplified by PCR, purified and mixed in equimolar concentration, and assembled by overlapping PCR by using the most external primers (see primers in Table 3). 5 µg of the obtained PCR product was used as donor DNA for natural transformation of strain SL12653 [pGhPxylTcomX$_{IO}$] (ComX$^+$). The correct insertion of the P_{32}-*cat* cassette in the targeted locus of SL12653 transformants was validated by PCR (see primers in Table 3). To obtain the final mutant strains, the thermosensitive vector pGhPxylTcomX$_{IO}$ was cured by growing the strains overnight at 37°C without erythromycin. The cultures were subsequently diluted and plated on M17G agar without erythromycin at 30°C. The resulting colonies were streaked in parallel on M17G plates with and without erythromycin. Absence of plasmid pGhPxylTcomX$_{IO}$ in Ery^S clones was validated by PCR. Thus, 3 Δ*comX* clones of SL12653 were obtained.

- *Xylose-induced natural transformation in SL12653.*

The *L. lactis* subsp. *lactis* SL12653 [pGhPxylTcomX$_{IO}$] was grown overnight at 30°C. Cells were washed twice in distilled water and OD600 was adjusted to 0.05 in M17 supplemented with 1% (w/v) xylose. Typically, 5 µg of DNA was added in 200 µl of inoculated medium and the culture was further incubated during 24 hours at 30°C. Cells were then spread on M17G agar plates supplemented with appropriate antibiotics and CFUs were counted after 48 hours of incubation at 30°C. The transformation frequency was calculated exactly as described above (see Standard natural transformation assay).

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology, biochemistry, microbiology, bacteriology, or related fields are intended to be within the scope of the following claims.

REFERENCES

Bachmann, H., W. L. de, M. Kleerebezem, and J. E. van Hylckama Vlieg. 2010. Time-resolved genetic responses of Lactococcus lactis to a dairy environment. Environ. Microbiol. 12:1260-1270.

Campbell, E. A., S. Y. Choi, and H. R. Masure. 1998. A competence regulon in Streptococcus pneumoniae revealed by genomic analysis. Mol. Microbiol. 27:929-939

David, B., Radziejwoski, A., Toussaint, F., Fontaine, L., Henry de Frahan, M., Patout, C.,van Dillen, S., Boyaval, P., Horvath, P., Fremaux, C. and P. Hols. 2017. Natural DNA transformation is functional in *Lactococcus lactis* subsp. *cremoris* KW2. Appl. Environ. Microbiol. *83*(16): 1–17

Ercan, O., M. Wels, E. J. Smid, and M. Kleerebezem. 2015. Genome-wide transcriptional responses to carbon starvation in nongrowing *Lactococcus lactis*. Appl. Environ. Microbiol. 81:2554-2561.

Fontaine, L., C. Boutry, M. H. de Frahan, B. Delplace, C. Fremaux, P. Horvath, P. Boyaval, and P. Hols. 2010. A novel pheromone quorum-sensing system controls the development of natural competence in *Streptococcus thermophilus* and *Streptococcus salivarius*. J. Bacteriol. 192:1444-1454.

Lee, M. S. and D. A. Morrison. 1999. Identification of a new regulator in Streptococcus pneumoniae linking quorum sensing to competence for genetic transformation. J. Bacteriol. 181:5004-5016.

Luo, P. and D. A. Morrison. 2003. Transient association of an alternative sigma factor, ComX, with RNA polymerase during the period of competence for genetic transformation in Streptococcus pneumoniae. J. Bacteriol. 185:349-358

Martín-Galiano and de la Campa 2003. High-Efficiency Generation of Antibiotic-Resistant Strains of Streptococcus pneumoniae by PCR and Transformation. Antimicrob Agents Chemother. 47(4):1257-1261

Peterson, S. N., C. K. Sung, R. Cline, B. V. Desai, E. C. Snesrud, P. Luo, J. Walling, H. Li, M. Mintz, G. Tsegaye, P. C. Burr, Y. Do, S. Ahn, J. Gilbert, R. D. Fleischmann, and D. A. Morrison. 2004. Identification of competence pheromone responsive genes in Streptococcus pneumoniae by use of DNA microarrays. Mol. Microbiol. 51:1051-1070

Terzaghi and Sandine 1975. Improved Medium for Lactic Streptococci and Their Bacteriophages. Applied Microbiology 29(6): 807-813

Todd, E.W., and L.F. Hewitt. 1932. A new culture medium for the production of antigenic streptococcal haemolysin. J. Pathol. Bacteriol. 35:973-975

Updyke, E.L., and M.I. Nickle. 1954. A dehydrated medium for the preparation of type specific extracts of group A streptococci. Appl. Microbiol. 2:117-118

Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual.

Sissler, M., Delorme, C., Bond, J., Dusko Ehrlich, S., Renault, P. and C. Francklyn. 1999. An aminoacyl-tRNA synthetase paralog with a catalytic role in histidine biosynthesis. Proc. Natl. Acad. Sci. 96:8985-8990

van Kranenburg, R., J. D. Marugg, I. I. van Swam, N. J. Willem, and W. M. de Vos. 1997.Molecular characterization of the plasmid-encoded *eps* gene cluster essential for exopolysaccharide biosynthesis in *Lactococcus lactis*. Mol. Microbiol. 24:387-397.

Ward, L. J., J. C. Brown, and G. P. Davey. 1998. Two methods for the genetic differentiation of *Lactococcus lactis* ssp. *lactis* and *cremoris* based on differences in the 16S rRNA gene sequence. FEMS Microbiol Lett. 166:15-20

Wegmann, U., M. O'Connell-Motherway, A. Zomer, G. Buist, C. Shearman, C. Canchaya, M. Ventura, A. Goesmann, M. J. Gasson, O. P. Kuipers, S. D. van, and J. Kok. 2007. Complete genome sequence of the prototype lactic acid bacterium *Lactococcus lactis* subsp. *cremoris* MG1363. J. Bacteriol. 189:3256-3270.

Wydau, S., R. Dervyn, J. Anba, E. S. Dusko, and E. Maguin. 2006. Conservation of key elements of natural competence in *Lactococcus lactis* ssp. FEMS Microbiol. Lett. 257:32-42.

CLAIMS

1. A method for transforming a strain of the *Lactococcus* genus with an exogenous DNA polynucleotide comprising the steps of:

(a) providing a strain of the *Lactococcus* genus, wherein said strain is transformable through natural competence;

(b) modulating the production of a ComX protein in said strain;

(c) contacting said strain of step (b) with an exogenous DNA polynucleotide in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) selecting a strain which has integrated the exogenous DNA polynucleotide into its genome.

2. A method according to claim 1, wherein the step of modulating the production of a ComX protein is performed by expressing a *comX* gene in said strain or increasing the expression of a *comX* gene in said strain.

3. A method according to claim 2, wherein said *comX* gene is an exogenous *comX* gene.

4. A method according to claim 3, wherein said exogenous *comX* gene is transferred into said strain by conjugation, transduction, or transformation.

5. A method according to claim 2, wherein said *comX* gene is the endogenous *comX* gene of said strain.

6. A method according to claim 5, wherein the method comprises carrying out step (b) and then carrying out step (c) or comprises carrying out step (b) and step (c) simultaneously.

7. A method according to any one of claims 1 to 6, wherein said ComX protein has the amino acid sequence of SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22 or an amino acid sequence having at least 90%, at least 95%, at least 97%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22 or an amino acid sequence having at least 90%, at least 95%, at least 97%, or at least 99% similarity to the amino acid sequence of SEQ ID NO: 2, SEQ ID

NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:22.

8. A method according to any one of claims 1 to 7, wherein said *comX* gene has the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 or a nucleotide sequence having at least 90%, at least 95%, at least 97% or at least 99% identity to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21.

9. A method according to any one of claims 1 to 8, wherein said medium of step (c) is a chemically defined medium.

10. A method according to any one of claims 1 to 9, wherein prior to step (c) said strain is incubated in a pre-culture medium, preferably wherein the pre-culture medium is a complex medium, more preferably wherein the pre-culture medium is M17G or THBG.

11. A method according to any one of claims 1 to 10, wherein said strain is incubated with the exogenous DNA polynucleotide for around 4-8 hours at around 30 °C and said medium of step (c) is supplemented with an osmo-stablizer, preferably wherein the osmo-stablizer is glycerol or mannitol, more preferably wherein the osmo-stabilizer is 5 % [v/v] glycerol or 5 % [w/v] mannitol

12. A method according to any one of claims 1 to 11, wherein said strain of the *Lactococcus* genus of step (a) is a strain of the *Lactococcus raffinolactis* species or a strain of the *Lactococcus lactis species*.

13. A method according to any one of claims 1 to 12, wherein said exogenous DNA polynucleotide used in step (c) is (obtained) from a strain of the same species, in particular of the same subspecies, as the strain provided in step (a).

14. A strain of the *Lactococcus* genus, in particular of the *Lactococcus lactis* or *Lactococcus raffinolactis* species obtained or obtainable by the method of any one of claims 1 to 13.

15. A method for identifying a strain of the *Lactococcus* genus which is transformable through natural competence comprising the steps of:

(a) providing a strain of the *Lactococcus* genus;

(b) transforming said strain with a plasmid expressing a *comX* gene having at least 90% identity, preferably having 100% identity, to the endogenous *comX* gene of said strain;

(c) contacting said strain obtained in step (b) with an exogenous DNA polynucleotide encoding a marker gene in a medium and incubating the resulting mixture for integration of the exogenous DNA polynucleotide into the genome of said strain; and

(d) determining the rate of recombination events;

wherein a rate of at least 1 x 10^{-6} transformants per µg of DNA is indicative of a strain which is transformable through natural competence.

16. A method according to any one of claims 1 to 13, wherein said strain of step (a) is identified using the method of claim 15.

17. A method according to any one of claims 1 to 13 and 16, wherein said strain of step (a) is identified using assay A.

		Dairy / Model	Dairy	Plant	Dairy / Model	Maize
		MG1363	**SK11**	**KW2**	**IL1403**	**SL12651 SL12653**
Reg	*comX*	+	*	+	+	+
Pilus assembly	*comGA*	+	Tn	+	+	+
	comGB	+	*	+	+	+
	comGC	+	+	+	+	+
	comGD	+	*	+	+	+
	comGE	+	+	+	+	+
	comGF	+	+	+	+	+
	comGG	+	+	+	+	+
	comC	+	*	+	+	+
DNA uptake	*comFA*	+	*	+	+	+
	comFC	+	+	+	+	+
	comEA	+	*	+	+	+
	comEC	*	Tn	+	+	+
DNA protection & recombination	*ssbB*	+	+	+	+	+
	coiA	*	+	+	+	+
	dprA	+	+	+	*	+
	recA	+	+	+	+	+

FIG. 1

A.


Max. sp. Lux activity (RLU OD600-1)
10^7
10^6
10^5
10^4
10^3
10^2
10^1
0
Ctl cl07 cl06 cl03 cl08 cl01 cl05 cl04 cl02
ComX+ (PcomGA-luxAB)

B.


Sp. Lux activity (RLU OD600-1) (—)
1.6 10^6
1.4 10^6
1.2 10^6
1.0 10^6
8.0 10^5
6.0 10^5
4.0 10^5
2.0 10^5
0
cl02
cl04
cl05
Ctl
1.0
0.1
0.0
OD600 (----)
0 1 2 3 4 5 6
Time (h)

FIG. 2

C.


MG1363 + comX_MG
1,6E+03
1,4E+03
1,2E+03
1,0E+03
8,0E+02
6,0E+02
4,0E+02
2,0E+02
0,0E+00
-2,0E+02
RLU/OD
10
1
0,1
O.D. (600nm)
0,00
2,00
4,00
6,00
8,00
10,00
Time (h)

D.


IL1403 + comX_IO
1,2E+04
1,0E+04
8,0E+03
6,0E+03
4,0E+03
2,0E+03
0,0E+00
-2,0E+03
RLU/OD
10
1
0,1
O.D. (600nm)
0,00
2,00
4,00
6,00
8,00
10,00
Time (h)

FIG. 2


Max. sp. Lux activity (RLU OD600-1)
3.5 10^6
3.0 10^6
2.5 10^6
2.0 10^6
1.5 10^6
1.0 10^6
5.5 10^5
5.0 10^4
Preculture medium
CDM
THBG
M17G
CDM
THBG
M17G
Final medium

FIG. 3

A.

```
                          10        20        30        40        50        60
                    ....|....|....|....|....|....|....|....|....|....|....|....|
MG1363              ATGCCTACAATTAACCAATTGGTACGCAAACCTCGTCGTGCTCAAGTGACTAAATCTAAA
MG1363_StrR         ....................................G.....................
KW2                 ....................................G.....................
KW2_transformant    ----------------------------------.....................
                                                       @

                          70        80        90       100       110       120
                    ....|....|....|....|....|....|....|....|....|....|....|....|
MG1363              TCACCAGCAATGAACGTTGGCTACAACAGCCGTAAAAAAGTACAAACTAAACTTGCAAGC
MG1363_StrR         ............................................................
KW2                 ............................................................
KW2_transformant    ............................................................

                         130       140       150       160       170       180
                    ....|....|....|....|....|....|....|....|....|....|....|....|
MG1363              CCACAAAAACGTGGAGTAGCAACTCGTGTTGGTACAATGACTCCTAAAAAACCTAACTCA
MG1363_StrR         ..........................................T.................
KW2                 .................................T..........................
KW2_transformant    ..........................................T.................
                                               #          $

                         190       200       210       220       230       240
                    ....|....|....|....|....|....|....|....|....|....|....|....|
MG1363              GCGCTTCGTAAATTCGCGCGTGTACGTCTTTCAAACCTTATGGAAGTAACAGCGTACATC
MG1363_StrR         ............................................................
KW2                 ............................................................
KW2_transformant    ............................................................

                         250       260       270       280       290       300
                    ....|....|....|....|....|....|....|....|....|....|....|....|
MG1363              CCAGGTATCGGACACAACCTCCAAGAACACAGTGTTGTACTTCTTCGTGGTGGACGTGTA
MG1363_StrR         ............................................................
KW2                 ............................................................
KW2_transformant    ............................................................

                         310       320       330       340       350       360
                    ....|....|....|....|....|....|....|....|....|....|....|....|
MG1363              AAAGACCTTCCAGGGGTACGTTACCATATCGTTCGTGGTGCACTTGATACAGCAGGTGTC
MG1363_StrR         ............................................................
KW2                 ............................................................
KW2_transformant    ............................................................

                         370       380       390       400       410
                    ....|....|....|....|....|....|....|....|....|....|....
MG1363              GCTGACCGTAAACAAAGCCGTTCTAAATACGGTGCTAAAAAACCAAAAGCTTAA
MG1363_StrR         ..................................................
KW2                 ..................................................
KW2_transformant    ..................----------------------------------
```

FIG. 4

B.


WT/ ComX+
Transformation rate (□)
Max. sp. Lux activity (RLU OD600-1) (◆)
4.5 10-5
4.0 10-5
3.5 10-5
3.0 10-5
2.5 10-5
2.0 10-5
1.5 10-5
1.0 10-5
5.0 10-6
1.0 10-7
10^7
10^6
10^5
10^4
10^3
10^2
10^1
ND ND ND ND ND ND ND
Ctl- cl07 cl06 cl03 cl08 cl05 cl01 cl04 cl02
BLD101 [pGhP32comX]

FIG. 4


1E+00
1E-01
1E-02
1E-03
1E-04
1E-05
1E-06
1E-07
1E-08
1E-09
1E-10
transformation rate
Treshold
RpsL*
comEC
mecA
ciaRH
covRS
ClpC
donor DNA

FIG. 5


ComEC-/ComX+
4.5 10-5
4.0 10-5
3.5 10-5
3.0 10-5
2.5 10-5
2.0 10-5
1.5 10-5
1.0 10-5
5.0 10-6
1.0 10-7
Transformation rate (□)
10^7
10^6
10^5
10^4
10^3
10^2
10^1
Max. sp. Lux activity (RLU OD600-1) (◆)
ND
ND
ND
ND
ND
Ctl+
cl01
cl03
cl02
cl04
Ctl-
BLD102 [pGhP32comX]

FIG. 6

A.


Transformation of SL12651 and SL12653
Transformation rate
3,0E-06
2,5E-06
2,0E-06
1,5E-06
1,0E-06
5,0E-07
0,0E+00
SL12651
SL12653
-DNA
+DNA

B.


Influence of donor DNA concentration
Transformation rate
6,0E-06
5,0E-06
4,0E-06
3,0E-06
2,0E-06
1,0E-06
0,0E+00
0
5
10
15
20
25
30
Donor DNA concentration (µg/ml)

C.


WT vs ComX-
Transformation rate
7,0E-06
6,0E-06
5,0E-06
4,0E-06
3,0E-06
2,0E-06
1,0E-06
0,0E+00
WT
ComX-
+DNA
-DNA

FIG. 7

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/083601

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12R1/46 C12N15/87
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N C12R

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, EMBASE, FSTA, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SANDRA WYDAU ET AL: "Conservation of key elements of natural competence in Lactococcus lactis ssp.", FEMS MICROBIOLOGY LETTERS, vol. 257, no. 1, 16 February 2006 (2006-02-16), pages 32-42, XP055382791, GB ISSN: 0378-1097, DOI: 10.1111/j.1574-6968.2006.00141.x cited in the application p.33 col.2 par.2, p.39 col.2 par.2, 3, p.40 col.2 par.1, 2 -----	1-17
Y	WO 2007/129072 A2 (NORWEGIAN UNIVERSITY OF LIFE S [NO]; JONES ELIZABETH [GB]; HAAVARSTEIN) 15 November 2007 (2007-11-15) p.2 l.16-25, p.4 l.1 - p.5 l.15 ----- -/--	1-17

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 February 2018	05/03/2018

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Bonello, Steve

1

Form PCT/ISA/210 (second sheet) (April 2005)

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EDOARDO ZACCARIA ET AL: "Control of Competence for DNA Transformation in Streptococcus suis by Genetically Transferable Pherotypes", PLOS ONE, vol. 9, no. 6, 26 June 2014 (2014-06-26), page e99394, XP055382803, DOI: 10.1371/journal.pone.0099394 p.2 col.1 par.2, p.2 col.1 par.2, p.4 col.2 par.4	1-17
Y	EP 2 248 823 A1 (AGRONOMIQUE INST NAT RECH [FR]) 10 November 2010 (2010-11-10) par.8, 10, 11, 20, 21	1-17
A	SOLVEIG SCHMID ET AL: "Alternative sigma factor [sigma]H activates competence gene expression in Lactobacillus sakei", BMC MICROBIOLOGY, BIOMED CENTRAL LTD, GB, vol. 12, no. 1, 12 March 2012 (2012-03-12) , page 32, XP021094889, ISSN: 1471-2180, DOI: 10.1186/1471-2180-12-32 p.2 col.1-2, p.7 col.2 par.2 - p.9 col.1 par.2, p.10 col.1	1-17

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2017/083601

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007129072 A2	15-11-2007	US 2010047384 A1	25-02-2010
		WO 2007129072 A2	15-11-2007
EP 2248823 A1	10-11-2010	DK 2424883 T3	06-03-2017
		EP 2248823 A1	10-11-2010
		EP 2424883 A1	07-03-2012
		ES 2617130 T3	15-06-2017
		US 2012040365 A1	16-02-2012
		US 2014322718 A1	30-10-2014
		WO 2010125091 A1	04-11-2010